

# **KDM6B promotes activation of the oncogenic CDK4/6-pRB-E2F pathway by maintaining enhancer activity in MYCN-amplified neuroblastoma**

Alexandra D'Oto<sup>1\*</sup>, Jie Fang<sup>1\*</sup>, Hongjian Jin<sup>2</sup>, Beisi Xu<sup>2</sup>, Shivendra Singh<sup>1</sup>, Anoushka Mullasseril<sup>1</sup>, Victoria Jones<sup>1</sup>, Ahmed Abu-Zaid<sup>1</sup>, Xinyu von Buttlar<sup>1</sup>, Bailey Cooke<sup>1</sup>, Dongli Hu<sup>1</sup>, Jason Shohet<sup>3</sup>, Andrew J Murphy<sup>1</sup>, Andrew M Davidoff<sup>1</sup>, Jun Yang<sup>1</sup>

<sup>1</sup>Department of Surgery, <sup>2</sup>Center for Applied Bioinformatics, St. Jude Children's Research Hospital, 262 Danny Thomas Place, Memphis, TN 38105

<sup>3</sup> Department of Pediatrics, University of Massachusetts Medical School, 55 Lake Avenue North, Worcester, MA 01655

\*equal contribution

Correspondence: Jun.Yang2@stjude.org or Andrew.Davidoff@stjude.org

## ABSTRACT

The H3K27me2/me3 histone demethylase KDM6B is over-expressed in neuroblastoma and is essential to neuroblastoma cell survival. While the KDM6B inhibitor, GSK-J4, has shown activity in *in vitro* and *in vivo* preclinical models, the mechanism of action remains poorly defined. We demonstrate that genetic and pharmacologic inhibition of KDM6B downregulates the pRB-E2F transcriptome and *MYCN* expression. Chemical genetic analyses show that high expression of the E2F transcriptome is positively correlated with sensitivity of cancer cells to GSK-J4. Mechanistically, inhibition of KDM6B activity 1) reduces the chromatin accessibility of E2F target genes and *MYCN*, 2) selectively leads to an increase of H3K27me3 but a decrease of the enhancer mark H3K4me1 at the CTCF and BORIS binding sites, which may, consequently, disrupt the long-range chromatin interaction of *MYCN* and E2F target genes, and 3) phenocopies the transcriptome induced by the specific CDK4/6 inhibitor palbociclib. Overexpression of CDK4/6 or *Rb1* knockout confers neuroblastoma cell resistance to both palbociclib and GSK-J4. A gene signature targeted by KDM6B inhibition is associated with poor survival of patients with neuroblastoma regardless of the *MYCN* status. These data indicate that KDM6B activity promotes an oncogenic CDK4/6-pRB-E2F pathway in neuroblastoma cells via H3K27me3-dependent enhancer-promoter interactions, providing a rationale to target KDM6B for high-risk neuroblastoma.

Key words: KDM6B, MYC, E2F, Neuroblastoma, CDK4/6, Palbociclib

## INTRODUCTION

KDM6 is a Jumonji domain-containing H3K27me3/me2 demethylase subfamily<sup>1-4</sup> that antagonizes the activity of polycomb repressive complex 2 (PRC2)<sup>5</sup>, the methyltransferase of H3K27. KDM6 consists of 3 members, KDM6A, KDM6B and UTY, although UTY has low lysine demethylase activity<sup>6</sup>. While KDM6A is believed to be a tumor suppressor and is mutated in many different types of cancer<sup>7,8</sup>, the function of KDM6B in cancer remains poorly defined. Early studies have shown that KDM6B contributes to activation of the *Ink4a/Arf* locus in fibroblasts in response to oncogenic stress<sup>9,10</sup>, and nuclear p53 protein stabilization in glioblastoma cells<sup>11</sup>. Loss of KDM6B enhances aggressiveness of pancreatic cancer cells<sup>12</sup>. These data suggest KDM6B might have a tumor suppressive function. However, KDM6B is overexpressed in various cancers<sup>13</sup>, indicating that KDM6B may play different roles depending on the cellular context. KDM6B appears to be essential for the initiation and maintenance of NOTCH-driven acute T-cell lymphoblastic leukemia<sup>14</sup>, regulates multiple myeloma cell growth and survival by modulating the MAPK pathway<sup>15</sup>, drives glioblastoma stem cell plasticity and drug tolerance by chromatin remodeling<sup>16</sup>, and promotes migration, invasion, and stem cell-like behaviors in hepatocellular carcinoma<sup>17</sup>. KDM6B is also involved in chemotherapy resistance<sup>18</sup>.

Neuroblastoma, the most common extra-cranial solid tumor in children, arises as a result of blocked differentiation of neural crest precursors (NCCs) during development of the sympathetic nervous system<sup>19,20</sup>. This aggressive malignancy accounts for 15% of cancer-related deaths in children<sup>21</sup>. Although outcomes for children with low- or intermediate-risk disease are excellent, fewer than 50% of children with high-risk disease survive despite aggressive multimodal therapy. In patients with high-risk disease, one key biological feature associated with poor prognosis is amplification of the *MYCN* oncogene (MNA)<sup>22</sup>. As a master lineage transcription factor that drives tumorigenesis, the functions of *MYCN* have been associated with targetable epigenetic modifiers<sup>23-25</sup>. Our previous study demonstrated that the histone demethylase KDM4B regulates *MYC* activity and promotes tumor growth and maintenance of neuroblastoma<sup>26</sup>. More recently, we identified a novel KDM4B inhibitor ciclopirox<sup>27</sup>, that inhibits tumor growth and promotes differentiation<sup>27</sup>. EZH2, the essential catalytic unit of the PRC2 complex, is a *MYCN* target that represses neuronal differentiation in a H3K27me3-dependent manner, leading to inactivation of a tumor suppressive program in neuroblastoma<sup>28</sup>.

In this study, we show that KDM6B is highly expressed in neuroblastoma and its genomic locus is broadly marked with transcriptionally active histone modifications and transcription factor binding. Using chemical genetic and epigenetic approaches, we show that KDM6B is involved in regulation of the key oncogenic CDK4/6-pRB-E2F pathway and expression of both *MYCN* and *C-MYC* proto-oncogenes.

Furthermore, the E2F transcriptome serves as a biological marker of KDM6 inhibitor sensitivity. Pharmacological inhibition of KDM6B activity alters the chromatin accessibility of E2F target genes and *MYCN*, induces the redistribution of H3K27me3 and the enhancer mark H3K4me1. We propose that this may disrupt the long-range chromatin interaction of the E2F transcriptome within the same topologically associated domains (TAD). At the level of transcriptome, KDM6B inhibition mimics the CDK4/6 inhibitor palbociclib. Cancer cells resistant to CDK4/6 inhibitor also are resistant to KDM6B inhibition. The gene signature targeted by KDM6 inhibition was associated with poor patient survival. Thus, our studies reveal that KDM6B regulates the oncogenic CDK4/6-pRB-E2F pathway in *MYCN*-amplified neuroblastoma, revealing a new mechanism of regulation of the E2F transcriptome by an epigenetic modulator.

## RESULTS

### ***KDM6B* is highly expressed in human neuroblastoma and is associated with a transcriptionally active epigenetic landscape**

We have previously shown that KDM6B, but not KDM6A or UTY, is essential for neuroblastoma cell survival<sup>27</sup>. To more clearly define the role of KDM6B in neuroblastoma, we first compared expression of KDM6 family genes in normal trunk neural crest-derived tissues, neuroblastoma being a neural crest-derived cancer of the peripheral nervous system<sup>29</sup>, with expression in tumors in 4 different neuroblastoma patient cohorts<sup>30-32</sup>. While expression of *KDM6A* and *UTY* did not show consistent differences in tumors as compared to normal tissue of neural crest origin, *KDM6B* expression was significantly elevated across all 4 neuroblastoma cohorts ( $p < 0.001$ ) (Figure 1A-1C). We also found that levels of *KDM6B* expression, but not *KDM6A* or *UTY*, in neuroblastoma cell lines were among the highest, across 40 different cancer lineages (Supplementary Figure 1A). Analysis of the data from 15 subtypes of pediatric cancers (PCGP project performed at St Jude) also showed *KDM6B* expression was among the highest in neuroblastoma (Supplementary Figure 1B). We then compared the RNA-seq transcript counts of *KDM6B*, *KDM6A* and *UTY* in three large neuroblastoma cohorts and found that expression of *KDM6B* was significantly higher than that of *KDM6A* or *UTY* (Figure 1D-1F).

Gene transcription status is usually associated with a distinct epigenetic landscape. For example, high levels of H3K4me1, H3K4me3 and H3K27Ac are marks of active gene transcription while high levels of H3K27me3 and H3K9me3 are marks of repressive gene transcription<sup>33</sup>. To determine whether high expression of KDM6B in neuroblastoma is associated with active epigenetic modifications, we investigated the epigenetic landscapes at the genomic loci of *KDM6B*, *KDM6A* and *UTY* in 7 primary



human neuroblastoma tissues sequenced at St Jude, 4 with MNA and 3 without MNA (Figure 1G, Supplementary Figure 2). Regardless of the *MYCN* status, the genomic locus of *KDM6B* across 22-kb in length in all 7 human neuroblastoma cell lines is occupied by RNA polymerase II, which drives gene transcription, in accordance with enrichment of active gene transcription marks H3K4me1, H3K4me2, H3K4me3, H3K27Ac, H3K9-K14Ac, and H3K36me3. However, no transcriptionally repressive H3K27me3 or H3K9me3 marks were occupied at the *KDM6B* locus. The broad occupation of H3K4me1 and H3K27Ac across the whole locus of *KDM6B* indicates that a super-enhancer<sup>34,35</sup> may regulate the expression of *KDM6B* in neuroblastoma. In contrast, the epigenetic landscapes at the *KDM6A* and *UTY* loci appeared to lack transcriptionally active gene transcription marks (Figure 1G, Supplementary Figure 2). The promoter region and gene body of *KDM6A* were occupied by the transcriptionally repressive marks H3K27me3 and H3K9me3, respectively. In summary, *KDM6B* is highly expressed in human neuroblastoma and its genomic locus is epigenetically modified for active gene transcription, which is distinct from its paralogs *KDM6A* and *UTY*.

#### **KDM6B regulates MYC expression**

We further validated the importance of KDM6B in neuroblastoma by assessing colony formation after knocking down *KDM6B* with 4 different siRNAs in BE2C cells (with MNA) and SK-N-AS cells (with high C-MYC activity). KDM6B depletion greatly reduced colony formation in both neuroblastoma cell lines, and was correlated with the KDM6B knockdown efficiency (Figure 1H,1I), consistent with our previous study<sup>27</sup>. In support of our data, neuroblastoma is the third most sensitive among 25 different cancer lineages that are sensitive to knockdown of KDM6B but not KDM6A (Supplementary Figure 3A, 3B), just below prostate cancer and myeloma, in a genome-wide shRNA screen (20 shRNAs per gene) in 709 cancer cell lines (DepMap dataset). Notably, depletion of KDM6B led to MYCN and C-MYC reduction in neuroblastoma cells (Figure 1I, Supplementary Figure 3C-F). Importantly, introduction of retroviral based KDM6B cDNA without its endogenous 3'UTR rescued the colony formation and MYCN expression in BE2C cells when endogenous KDM6B was depleted using a siRNA designed to target its 3'UTR (Figure 1J-L), demonstrating the phenotype induced by KDM6B depletion is not due to an off-target effect. Conversely, overexpression of KDM6B in BE2C cells reduced H3K27me3, increased MYCN expression and promoted cell proliferation (Supplementary Figure 3G, H). Additionally, we found that KDM6B also regulated MYC expression in other cancer lineages such as lung cancer, osteosarcoma, and colorectal cancer cells and that this was independent of p53 status (Supplementary Figure 3I-L). These data indicate that KDM6B is needed for MYC expression in cancer cells.

## KDM6B regulates a pRB-E2F transcription program in neuroblastoma

To investigate the molecular function of KDM6B in neuroblastoma, we performed RNA-seq followed by gene set enrichment analysis (GSEA) after knockdown of KDM6B in MYCN-amplified (BE2C and KELLY) and MYCN-non-amplified cells (SK-N-AS, SK-N-FI). Strikingly, GSEA results showed that the top hits of KDM6B downstream targets were enriched with E2F gene sets, *Rb1* knockout signatures (*Rb1* encodes pRB, is a negative regulator of E2F activity<sup>36</sup>) and other cell cycle gene signatures (Figure 2A-2C, Supplementary Figure 4A, 4B), in the two MYCN amplified cell lines. Motif analysis of the KDM6B target genes also revealed that they were mainly enriched with E2F binding motifs (Table 1). These data indicate that KDM6B regulates the transcriptome of the E2F pathway in MYCN-amplified neuroblastoma cells. The E2F transcription factors are critical regulators of cell cycle progression by directly regulating more than 100 genes including those encoding cyclins<sup>37</sup>. Early studies showed that E2F also binds to promoters of *C-MYC* and *MYCN* to regulate their expression<sup>38,39</sup>. GSEA data revealed that MYC targets were also significantly downregulated by KDM6B depletion (Figure 2A). Interestingly, the top signatures upregulated by KDM6B knockdown in SK-N-FI were enriched with E2F gene sets (Supplementary Figure 4C, 4D), although C-MYC expression was reduced (Supplementary Figure 3F). However, the E2F gene signatures were less affected in SK-N-AS cells than BE2C, KELLY and SK-N-FI although one E2F3 gene set was downregulated by KDM6B knockdown (Supplementary Figure 3E, 3F).

We further investigated KDM6B function using pharmacologic inhibition. GSK-J1 is the only selective KDM6 inhibitor available<sup>40</sup>, but, unfortunately, it is unable to penetrate cells. To make GSK-J1 cell-permeable, GSK-J1 was modified by adding an ester (new reagent was named GSK-J4)<sup>40</sup>. Thus, GSK-J4 is not itself a chemical tool for direct KDM inhibition, but was designed specifically to enable efficient intracellular delivery of GSK-J1 into cells. The intracellular conversion of the ester pro-drug is complete within 15 min after which levels of intracellular GSK-J4 are negligible<sup>41</sup>. Once entering cells, GSK-J4 converts back to GSK-J1, consequently inhibiting KDM6 (Supplementary Figure 5A)<sup>40</sup>. To validate this and profile the selectivity of GSK-J1/GSK-J4, we used an AlphaLISA approach, a method that tests the *in vitro* inhibitory activity of GSK-J1 and GSK-J4 against purified KDMs (KDM2A, KDM3A, KDM4A, KDM5A, KDM6A, KDM6B). We confirmed that GSK-J1 was selectively effective against KDM6A and KDM6B, had some effect on KDM5A but showed no activity against KDM2A, KDM3A and KDM4A (Supplementary Figure 5B), a result consistent with published GSK data<sup>40</sup>. However, GSK-J4 showed no *in vitro* activity against all tested KDMs (Supplementary Figure 5C). While GSK-J4 could have off-target

effects when administered at high concentrations, the concentration we used in cells (2.5  $\mu$ M) only induced the upregulation of H3K27me3, but not H3K9me3, H3K36me3 and H3K4me3 (Supplementary Figure 5D), three other major histone methylation sites of H3, indicating that GSK-J4 induced its cellular effect by selectively targeting KDM6 but not other KDMs. Additionally, a selective KDM5 inhibitor, KDM5-C70<sup>42</sup>, showed no effect on neuroblastoma cell proliferation even when administered at very high concentrations (40 $\mu$ M) (Supplementary Figure 5E, 5F).

Treatment of neuroblastoma cells and normal human fibroblasts (HS68) with GSK-J4, in a colony formation assay, showed that GSK-J4 inhibited colony formation in a concentration-dependent manner, with a significant effect observed in the majority of cell lines at concentrations of 1.0-2.0 $\mu$ M (Supplementary Figure 6A). However, HS68 cells were unaffected by GSK-J4. Consistent with these results, another recent study showed that GSK-J4 has a potent effect on neuroblastoma cell survival<sup>43</sup>. To define the molecular mechanism of GSK-J4 action on neuroblastoma cells, we performed global gene expression profiling for GSEA analysis after GSK-J4 treatment of BE2C cells. GSK-J4 induced a very similar transcriptome profile as depletion of KDM6B and the gene sets most significantly downregulated by this inhibitor were enriched with cell cycle, *Rb1* knockout and E2F pathways (Figure 2D-2F). Transcription factor motif binding analysis showed that genes downregulated by GSK-J4 were greatly enriched with E2F binding (Table 2). Again, MYCN and C-MYC expression were also downregulated by GSK-J4 treatment (Supplementary Figure 6B-6D), consistent with KDM6B depletion (Supplementary Figure 3). Re-analysis of an independent RNA-seq data set<sup>43</sup> also showed that KDM6 inhibition led to downregulation of gene sets enriched with *Rb1* knockout and DREAM complex (dimerization partner, RB-like, E2F and multi-vulval class B) in neuroblastoma cells (Supplementary Figure 7). Thus, GSK-J4 phenocopied KDM6B depletion in neuroblastoma cells and, therefore, its therapeutic effect may be mediated through inhibition of KDM6B. Taken together, genetic and pharmacologic inhibition of KDM6B predominantly leads to downregulation of the pRB-E2F transcriptional program, particularly in MYCN-amplified neuroblastoma cells.

## **Pharmacogenetics reveals that the E2F transcriptome is associated with sensitivity to KDM6B inhibition**

While the presence of KDM6B is a prerequisite for GSK-J4 activity in neuroblastoma cells<sup>43</sup>, expression levels of KDM6B do not correlate with GSK-J4 sensitivity<sup>43</sup>. A biomarker that predicts therapy response is critical for patient stratification. Since KDM6B inhibition appears to effect its anti-tumor activity through downregulation of the E2F transcriptome, we hypothesized that high levels of the E2F

transcriptome may correlate with the response of cancer cells to KDM6B inhibition. The gene signatures induced by chemical (i.e., small-molecule) or genetic perturbations (i.e., siRNA knockdown) can be used to connect unknown mechanisms of action (MoA) of chemical probes. Differential gene expression has been correlated with patterns of small-molecule sensitivity across many cell lines to illuminate the actions of compounds whose MoA are unknown<sup>44,45</sup>. The Cancer Therapeutic Response Portal correlated the sensitivity patterns of 481 compounds including GSK-J4 with 19,000 basal transcript levels across 823 different human cancer cell lines and identified selective outlier transcripts<sup>44,45</sup>, which allowed us to interrogate whether the KDM6B inhibitor activity was correlated with specific transcripts. The E2F genes such as *E2F8* were the ones most significantly affected by KDM6B inhibition (Figure 2). *E2F8* is an atypical E2F and downstream target of E2F1-3<sup>46</sup>. We chose *E2F8* as a representative gene to correlate E2F pathway activity with drug effect. Strikingly, GSK-J4 ranked highest among the top compounds whose cellular activity was correlated with *E2F8* expression (Pearson correlation  $R=-0.528$ , z-score = -4.56, Figure 3A). We arbitrarily chose 13 cell lines with high *E2F8* expression as group A, and 8 cell lines with low *E2F8* expression as group B, which had high sensitivity and low sensitivity to GSK-J4, respectively (Figure 3B, Supplementary Table 1). We then used GSEA to infer the pathways that differed in the two groups. We found that the pRB-E2F gene sets were the most significant hits in group A cell lines (Figure 3C, 3D). The genes highly expressed in group A cells were profoundly enriched with E2F transcription factor binding motifs (Supplementary Table S2), and most of the top 50 genes such as *E2F1* and *E2F8* are involved in regulation of the cell cycle (Supplementary Figure 8A). MYC signatures were also enriched in group A cells (Supplementary Figure 8B-8D). We also selectively investigated several other E2F genes including *ASF1B*, *CDK2* and *E2F1*, all of which were positively correlated with GSK-J4 sensitivity (Supplementary Figure 8E-8G). Therefore, cancer cells with high E2F activity appear to be more sensitive to KDM6B inhibition.

To specifically investigate the conclusion that high E2F activity serves as a biomarker for sensitivity to KDM6B inhibition in neuroblastoma, we categorized neuroblastoma cell lines into two groups according to their  $IC_{50}$  to GSK-J4<sup>43</sup>. GSEA analysis of RNA-seq data of these cell lines showed a very similar transcriptome pattern to KDM6B knockdown or GSK-J4 inhibition for those with lower  $IC_{50}$  to GSK-J4 (more sensitive), which were enriched with E2F and MYC gene signatures (Figure 3E). For example, SK-N-FI cells with high E2F transcriptome expression were more sensitive to GSK-J4 than SK-N-SH cells (Figure 3F), which had lower expression of the E2F transcriptome. The genes highly expressed in neuroblastoma cells that were more sensitive to GSK-J4 were predominantly enriched with E2F transcription factor binding motifs (Table 3). Taken together, these data demonstrate that a high E2F gene

signature is correlated with GSK-J4 sensitivity, and thus it may serve as a biomarker for effectiveness of KDM6B inhibitors in cancer treatment in the future. These data also further support that KDM6B regulates the E2F transcriptome.

## **Inhibition of KDM6B activity reduces the chromatin accessibility of E2F target genes and *MYCN***

To understand how KDM6B regulates the E2F pathway, we performed Assay for Transposase-Accessible Chromatin with high-throughput sequencing (ATAC-seq) after 24h and 48h of GSK-J4 treatment, for mapping genome-wide chromatin accessibility<sup>47</sup>. The 24h GSK-J4 treatment resulted in upregulation of 8386 nucleosome-free, open chromatin regions (log2 fold change  $\geq 0.5$ ,  $p < 0.05$ , Figure 4A), 46.9% of which were located at the annotated promoter regions (within 2-kb from transcription start site, TSS) and 39% of which were located at the annotated enhancer regions (2-50kb distance from TSS). The rest (14.1%) were located at more distal regions. However, 9574 nucleosome free, open chromatin regions were downregulated by GSK-J4 treatment (Figure 4A), only 18.5% of which were located at the promoter regions and 61.8% of which were located at enhancer regions, while 19.7% were located at more distal regions. The 48h GSK-J4 treatment further enhanced its effect on DNA accessibility, resulting in an increase of 13546 and decrease of 11027 peaks, respectively (Figure 4A). The proportions of the annotated regions tended to be similar to that of 24h treatment. Among the regions with upregulated chromatin accessibility, 57.6% were located at promoter regions, 29.5% were located at enhancer regions, and 12.9% were located at more distal regions (Figure 4A). Among the regions with downregulated chromatin accessibility, 17.9% were located at promoter regions and 57.8% were located at enhancer regions, while 24.3% were located at more distal regions (Figure 4A). We further assessed whether altered chromatin accessibility was associated with changes in gene expression. Indeed, the genes annotated with differential accessibility regions (DARs) at promoters or enhancers were significantly enriched in differentially expressed genes by GSK-J4 treatment (Supplementary Figure 9). For example, DNA accessibility at the promoter region of the oncogene *AKT1* was reduced by GSK-J4, and one additional peak at a potential enhancer region near the long non-coding RNA *LINC00638* was also decreased (Figure 4B). The reduction of chromatin accessibility was consistent with the reduced expression of *AKT1* transcripts. *AKT1* is a key molecule in the PI3K-mTOR pathway<sup>48</sup>, and E2F upregulates AKT activity through a transcription-dependent mechanism<sup>49</sup>. *E2F8*, whose expression was downregulated by KDM6B knockdown and GSK-J4 treatment, did not show significant changes in DNA accessibility within its promoter region. However, several peaks at the distal region of *E2F8* which extended to the adjacent *NAV2* locus were altered by GSK-J4 (Figure 4C). Notably, our RNA-seq analysis showed that the *NAV2*



locus is not expressed in BE2C cells (Figure 4C). These data suggest that *E2F8* expression might be regulated by a distal enhancer that is silenced by KDM6B inhibition. Similarly, we did not observe significant changes at the promoter regions of *MYCN*, and cell cycle genes (*CCNE1*, *BUB1* and *BIRC5*); however, the DNA accessibility at the distal regions of these genes were reduced (Supplementary Figure 10A-10D). The downregulation of gene expression by GSK-J4 was not always correlated with reduction of DNA accessibility. For example, chromatin accessibility at the *AURKB* promoter was increased by GSK-J4 although its transcript expression was reduced (Supplementary Figure 10E), suggesting that the open chromatin may recruit transcription suppressors to repress its gene transcription. For *CDKN1A*, which encodes p21 to inhibit the CDK2/Cyclin E complex during S phase of the cell cycle, the DNA accessibility at its promoter and enhancer regions was enhanced, consistent with its transcript induction by KDM6B inhibition (Supplementary Figure 10F).

Transcription factor motif analysis of the ATAC-seq data using genomic footprinting demonstrated that E2F binding motifs had reduced DNA accessibility (Figure 4D, 4E). Downregulated open chromatin regions were also observed for MYCN and MYC/MAX binding motifs (Figure 4E). These data indicate that KDM6B inhibition impacts the chromatin accessibility and transcription of E2F and MYC pathway genes.

### **KDM6B inhibition induces an increase of H3K27me3 but a decrease of the enhancer mark H3K4me1 at CTCF and BORIS binding sites**

To examine the impact of KDM6B inhibition on epigenetic marks, we performed Cleavage Under Targets & Tagmentation (CUT&Tag) to assess the alterations of H3K27me3, the KDM6B substrate, and H3K4me1, the enhancer mark, after KDM6B knockdown and GSK-J4 treatment of BE2C cells. CUT&Tag is an epigenomic profiling strategy that overcomes shortcomings of ChIP-seq<sup>50</sup>. In CUT&Tag, the H3K27me3 and H3K4me1 were bound in situ by specific antibodies, which were then tethered to a protein A-Tn5 transposase fusion protein. Activation of the transposase efficiently generates fragment libraries with high resolution and exceptionally low background<sup>50</sup>. The CUT&Tag library size for each sample was adjusted by E. Coli residual genomic DNA as a spike-in scaling factor, which was used to normalize the read counts for the downstream differential analysis. KDM6B inhibition induced a modest increase of global H3K27me3 peaks (Supplemental Table 3, Supplemental Figure 11A). We specifically assessed the H3K27me3 in the differentially expressed genes induced by KDM6B inhibition. Among the genes differentially regulated by KDM6B knockdown and GSK-J4 treatment, the patterns of H3K27me3 changes tended to be similar in both groups (Figure 5A), suggesting that GSK-J4 mainly acts through

KDM6B to modulate the H3K27me3 levels. In particular, the H3K27me3 signals at the super-enhancer region of *MYCN* (the genomic region between *MYCN* and *FAM149A*, with a noncoding RNA *GACAT3* between both of them<sup>23,51</sup>) were most significantly upregulated by KDM6B knockdown or GSK-J4 treatment (Figure 5C, Supplemental Figure 11A), which is consistent with the downregulation of *MYCN* by KDM6B inhibition. We further assessed H3K4me1, the enhancer mark, using CUT&Tag after KDM6B knockdown and GSK-J4 treatment (Supplemental Table 4). Similar patterns of H3K4me1 changes were observed in both groups (Figure 5B). Interestingly, while more peaks of H3K4me1 were increased in genes downregulated by KDM6B inhibition, the super-enhancer region of *MYCN* showed most significant downregulation of H3K4me1 although GSK-J4 also induced an increase of several peaks at this region (Figure 5C, Supplemental Figure 11B), suggesting that *MYCN* super-enhancer region is particularly susceptible to perturbation of KDM6B inhibition.

The alterations of H3K27me3 and H3K4me1 by KDM6B inhibition mainly occurred at non-promoter regions (Supplemental Figure 11C), suggesting that KDM6B has a major impact on distal regulatory elements of transcription. Transcriptional factor motif analyses of H3K27me3 and H3K4me1 peaks revealed that KDM6B inhibition dominantly led to an increase of H3K27me3 but a decrease of H3K4me1 at the CTCF and BORIS binding sites (Figure 5D, E), and no enrichment with *MYCN* or E2F binding sites. CTCF and BORIS (also named CTCFL) play an important role in chromatin looping and long-range chromatin interactions<sup>52-54</sup>. H3K4me1 is an essential feature of enhancers and is bound by multiple chromatin-associated factors such as BAF complex and Cohesion<sup>55</sup>, which facilitate enhancer-promoter looping<sup>56,57</sup>. Since the majority of upregulated H3K27me3 peaks were located at distal regulatory regions, we hypothesized that the H3K27me3 changes at these distal regions repressed transcription of *MYCN* and E2F target genes via alteration of chromatin structure and enhancer/promoter interactions. To investigate this possibility, we cross-referenced the Hi-C chromatin conformation of BE2C cells. Interestingly, *MYCN* is located at the same topologically associated domain (TAD) as the *GACAT3* and *FAM149A* loci, marked as a super-enhancer by broad H3K27Ac occupancy, showing dysregulated H3K27me3 and H3K4me1 by KDM6B inhibition (Figure 5C). A TAD domain is a self-interacting genomic region that regulates gene expression by limiting the enhancer-promoter interaction to each TAD<sup>58,59</sup>. Chromatin interaction was observed across this region (Figure 5F), supporting the hypothesis that KDM6B inhibition may disrupt the chromatin interaction, leading to reduced transcription of *MYCN*. Similarly, we found the *E2F8* gene locus showed multiple chromatin interactions with adjacent genes within the TAD, particularly to the *NAV2* locus (Supplemental Figure 11D, E). Taken together,

these data suggest that KDM6B inhibition might alter the long-range interactions of *MYCN* and E2F target genes in TAD, repressing the *MYCN* and E2F regulated transcriptome.

### **GSK-J4 reduces the expression of the PRC2 complex**

The homeostasis of H3K27me3 is balanced by PRC2 and KDM6<sup>5</sup>. More H3K27me3 peaks were expected by KDM6 inhibition. However, GSK-J4 treatment did not lead to expected high number loci of H3K27me3 (Supplemental Figure 11A). To explain this discrepancy, we examined the expression of the PRC2 complex. The key PRC2 components (EZH2, SUZ12 and EED) have been shown to be pRB-E2F targets<sup>60,61</sup>. Consistent with the data that KDM6B inhibition mainly downregulated an pRB-E2F transcriptome, GSK-J4 treatment indeed reduced the expression of the PRC2 complex (Supplementary Figure 12A). However, the expression of global H3K27me3 was minimally affected, indicating that the expected H3K27me3 upregulation by KDM6 inhibition is counterbalanced by reduced expression of PRC2. A recent study identified a 37-gene signature of EZH2<sup>28</sup>, which is repressed by EZH2 and silenced in *MYCN*-amplified high-risk neuroblastoma. GSEA analysis revealed that this 37-gene signature was significantly associated with the GSK-J4 treatment (Supplementary Figure 12B, 12C), suggesting that KDM6B inhibition consequently downregulates the functions of PRC2, leading to the induction of tumor-suppressive program repressed by EZH2.

### **Inhibition of KDM6B mimics CDK4/6 inhibitor Palbociclib**

To further investigate the biological functions of KDM6B, we integrated the KDM6B downstream target genes with information from the Library of Integrated Network-Based Cellular Signatures (LINCS) data. LINCS data is composed of tens of thousands of gene sets, indicative of the transcriptional responses to a large library of chemical compounds<sup>62</sup>. With this approach, we found that genes downregulated by KDM6B knockdown in neuroblastoma cells (Supplementary Table S5) overlapped significantly with the transcriptomes downregulated by palbociclib (Figure 6A), a specific CDK4/6 inhibitor that acts upstream of the E2F pathway in cell cycle regulation. Similarly, genes downregulated by GSK-J4 (Supplementary Table S6) also significantly overlapped the transcriptomes downregulated by palbociclib (Figure 6B). CDK4/6 inhibitor signatures being identified among the most correlated signatures with KDM6B knockdown or GSK-J4 treatment further demonstrated that KDM6B is mainly involved in regulation of the E2F pathway. To corroborate these findings, we treated 4 different neuroblastoma cell lines (2 with MNA and 2 without MNA) with palbociclib and performed RNA-seq for differential gene expression analyses. By comparing the genes most significantly downregulated by palbociclib among these cell lines via Venn program (Supplementary Figure 13), we extracted 89 common genes (Supplementary Table S7).



GSEA results showed that the 89-gene signature was significantly enriched within gene sets downregulated by KDM6B knockdown (Figure 6C) or GSK-J4 treatment (Figure 6D). Although single drug treatment effectively inhibited colony formation in a dose dependent manner, the combination of GSK-J4 and palbociclib did not enhance the inhibitory effect on colony formation of BE2C cells, as shown by colony formation and Bliss combination index (Figure 6E, 6F), likely because both drugs target the same pathway. However, GSK-J4 greatly enhanced the effect of 17-DMAG, an HSP90 inhibitor (Supplementary Figure 14A, 14B), and JQ-1, a bromodomain inhibitor that targets BRD4<sup>63</sup> (Supplementary Figure 14C, 14D). Interestingly, we observed some degree of synergy of GSK-J4 and palbociclib, as well as 17-DMAG and JQ-1 in SK-N-AS cells (Supplementary Figure 14E-G), the non-MYCN amplified cells with less impact on E2F pathways by KDM6B inhibition.

### **Cancer cells with acquired CDK4/6 inhibitor resistance are less responsive to GSK-J4**

Upon mitogen stimulation, CDK4 and CDK6 phosphorylate the pRB protein, leading to release of E2F transcription factors from pRB for gene transcription<sup>64</sup>. CDK4/6 inhibitors including palbociclib showed promising efficacy in ER<sup>+</sup>/HER2<sup>-</sup> breast cancer and have been approved for clinical use<sup>65,66</sup>. Over 100 clinical trials of CDK4/6 inhibitors for a variety of cancers are currently in progress<sup>65</sup>. However, acquired resistance to CDK4/6 inhibitors, as observed during breast cancer treatment, is expected and the mechanism involves amplification of *CDK6* or loss of function of *Rb1*<sup>65,66</sup>. To test if these mechanisms also diminish the effect of GSK-J4, we transduced the BE2C cells with lentiviral based CDK4 and CDK6 (Figure 6G). Overexpression of CDK4 or CDK6 conferred expected resistance in neuroblastoma cells to palbociclib, as shown by colony formation and EC50 shift (Figure 6H, I). Cells which overexpressed CDK4 or CDK6 also gained resistance to GSK-J4, although a higher concentration of GSK-J4 at 2.5μM was still able to kill them (Figure 6H, 6J). We then generated an *Rb1* knockout cell line for testing the response to GSK-J4 and palbociclib (Figure 6K). As expected, loss of *Rb1* conferred resistance to palbociclib (Figure 6L). Similarly, the *Rb1* knockout cells were also resistant to GSK-J4 treatment in comparison with the *Rb1* wildtype cells (Figure 6M). Similar to the CDK4 or CDK6 overexpressing cells, the combination of palbociclib and GSK-J4 was not synergistic (Figure 6M). These data further demonstrate that KDM6B acts on the same pathway as pRB-E2F in neuroblastoma.

### **A gene signature targeted by KDM6B inhibition is associated with poor outcome**

To correlate the clinical relevance of target genes of KDM6B inhibition, we identified a 149-gene signature (Supplementary Table 8) that was commonly downregulated by GSK-J4 in BE2C and three

other neuroblastoma cell lines (IMR5, LAN5 and SK-N-FI)<sup>43</sup>. Among these 149 genes, 85 were highly expressed in the high-risk neuroblastomas while 20 were highly expressed in the low-risk neuroblastomas (Supplementary Table 9). Based on the expression levels of these differentially expressed genes in neuroblastomas, they were categorized into 4 clusters (Figure 7A). Cluster 3 and 4 neuroblastomas expressed higher levels of the GSK-J4 signature, and were enriched with high-risk, high-stage and MYCN-amplified tumors. While patients in clusters 1 and 2 showed excellent event-free and overall survival, clusters 3 and 4 patients had a significantly worse outcome (Figure 7B, 7C). No difference was observed between clusters 1 and 2. Cluster 4 showed a poorer survival than that of cluster 3, in line with the higher expression of GSK-J4 target genes in cluster 4. *MYCN* amplification (MNA) is a well-known poor prognostic risk factor in neuroblastoma. To investigate whether the correlation of the GSK-J4 signature with patient outcome was affected by MNA status, we compared the event-free survival of clusters 3 and 4 with MNA. The results showed that cluster 4, which had higher levels of GSK-J4 signature, was still correlated with a poorer event-free survival of patients with MNA although the overall survival was not statistically significant (Figure 7D, 7F). However, in stage 4 patients, cluster 4 showed significantly worse outcome in both event-free and overall survival than that of cluster 3 (Supplementary Figure 15). In high-risk patients, cluster 4 had a significantly worse outcome in event-free survival compared to cluster 3, but there was no difference in overall survival (Figure 7E, G). These data indicate that, in stage 4 or MNA patients, higher expression levels of the GSK-J4 signature is a high-risk factor.

## DISCUSSION

Despite one recent study suggesting that KDM6B might be tumor suppressive in neuroblastoma<sup>67</sup>, we and others have found that KDM6B plays an important role in MYC-driven tumorigenesis and that pharmacologically targeting KDM6B by the small molecule GSK-J4 is therapeutically efficacious in multiple tumor models<sup>14,27,68-71</sup>, including high-risk neuroblastoma<sup>43</sup>. However, the anticancer mechanisms of KDM6B inhibition are poorly understood. Here we show that *KDM6B* is significantly over-expressed in human primary neuroblastoma in comparison with its paralogs *KDM6A* and *UTY*. Strikingly, the 22-kb genomic locus of *KDM6B* is heavily occupied by active gene transcription marks, including H3K4me1, H3K27Ac, BRD4 and RNA polymerase II binding while the *KDM6A* and *UTY* loci lack such histone modifications and transcription factor binding. These data explain why *KDM6B* is expressed at much higher levels than *KDM6A* and *UTY* in neuroblastoma. The long-distance broad marks at the KDM6B locus with H3K4me1 and H3K27Ac suggest *KDM6B* expression is under the control of a

super-enhancer, a large cluster of transcriptional enhancers that drive expression of genes that define cell identity<sup>72</sup>. We further found that KDM6B is predominantly involved in regulation of MYC expression and downstream target genes of the pRB-E2F pathway. Genetic and pharmacologic inhibition of KDM6B consistently repressed the expression of MYCN and C-MYC, and the transcriptome of E2F target genes. These results support previous studies demonstrating that E2F and MYC are functionally associated<sup>38,39</sup>, and that E2F drives MYC expression. MYC also regulates E2F expression and requires distinct E2F activities to induce S phase and apoptosis<sup>73</sup>. Moreover, a close association between E2F and MYC binding sites and their target genes has been observed<sup>74</sup>. Nevertheless, the impact of KDM6B inhibition on E2F pathways was more dramatic in MYCN-amplified neuroblastoma cells.

E2F deregulation in cancer often occurs through loss-of-function of the pRB tumor suppressor<sup>75</sup>. The E2F transcription factors (E2F1, E2F2, and E2F3a) bind at target gene promoters in complexes with their dimerization partner (DP1 or DP2) and pRB<sup>36</sup>, which suppresses target gene transcription through the recruitment of chromatin modifiers and remodeling factors such as HDAC and EZH2<sup>36,76</sup>. During the G1 phase of the cell cycle, oncogenes such as Ras induce D-type cyclins to activate cyclin dependent serine/threonine kinases CDK4 and CDK6, which phosphorylate pRB, consequently leading to release of E2F transcription factors from pRB, allowing for cell proliferation<sup>64</sup>. While *Rb1* loss is very rare in neuroblastoma, several studies have shown that the cyclin D/CDK4/CDK6 pathway is hyperactive in neuroblastoma<sup>77-82</sup>. Genome-wide CRISPR and shRNA screening demonstrated that knockout of *CDK4* or *CDK6* inhibited neuroblastoma cell proliferation/survival while *Rb1* knockout promoted cell proliferation (<https://depmap.org/portal/>). A majority of neuroblastoma models with MNA are sensitive to CDK4/6 inhibition<sup>83</sup>. These data indicate that the deregulated E2F pathway is essential to neuroblastoma. The genetic and pharmacologic KDM6B inhibition results in a predominant reduction of the E2F transcriptome and MYC, which may account for the therapeutic effect of KDM6B blockade in neuroblastoma. In addition, the transcriptome of KDM6B inhibition mimics the CDK4/6 inhibitor, palbociclib. When cells gained resistance to palbociclib by overexpressing CDK4/6 or by *Rb1* knockout, they also gained resistance to GSK-J4. Thus, these data further support that KDM6B regulates the CDK4/6-pRB-E2F pathway in neuroblastoma.

Intriguingly, while transcriptome, chemical genetics and ATAC-seq analyses show that KDM6B inhibition impacts MYCN and the E2F transcriptome, the loci of H3K27me3 alterations were not enriched with MYCN and E2F genes. As the majority of enhancer mark H3K4me1 and H3K27me3 peaks altered by KDM6B inhibition were located at distal non-promoter regions, one possible explanation is that KDM6B inhibition disrupted the long-range chromatin interaction between its targets and the

regions with altered H3K27me3 and H3K4me1 because H3K4me1 functions to mediate the enhancer-promoter looping<sup>56,57</sup>. H3K4me1 is basically catalyzed by KMT2 family methyltransferases. Previous studies have shown that KMT2 members can form complexes with KDM6<sup>84-86</sup>, suggesting a concerted mechanism for transcriptional activation in which cycles of H3K4 methylation by KMT2 are linked with the demethylation of H3K27<sup>84-86</sup>. The transcriptional factor motif analysis showed that CTCF and BORIS binding motifs are the major sites impacted by altered H3K27me3 and H3K4me1. KDM6B inhibition specifically leads to increased H3K27me3 at CTCF and BORIS binding sites while H3K4me1 at CTCF and BORIS binding sites are selectively reduced. These data suggest that increased H3K27me3 displaces H3K4me1 modifiers (highly likely the H3K4me1 methyltransferase KMT2) from CTCF and BORIS sites, consequently disrupting the enhancer activity. Previous studies have shown that enhancers, CTCF and H3K4me1 peaks overlap<sup>87</sup>. CTCF regulates the long-range chromatin interactions at enhancers. Thus, KDM6B inhibition may disrupt the chromatin interaction at its target genes. *MYCN* and many E2F target genes reside in the same topologically associated domains (TAD) as the regions with elevated H3K27me3 by KDM6B inhibition. TADs include chromatin loops that mediate promoter–enhancer contacts that regulate gene expression<sup>58,59</sup>. Our CUT&Tag data showed that the super-enhancer region of *MYCN*, which exhibits long-range chromatin interactions within a TAD domain, has the most significant changes of H3K27me3 and H3K4me1 by KDM6B knockdown and GSK-J4 treatment, in line with the reduction of *MYCN* expression by KDM6B inhibition. In erythroid cells, long-range control of epigenetic regulation has been observed in that KDM6B is recruited to the enhancer regions to erase H3K27me3, consequently evicting the gene silencing PcG protein for a high rate of transcription<sup>88</sup>. During early differentiation steps, the embryonic stem cell factor Tbx3 associates with KDM6B at the enhancer element of the *Eomes* locus to allow enhancer-promoter interactions<sup>89</sup>. This spatial reorganization of the chromatin primes the cells to respond to Activin signaling. In neural stem cells, SMAD3 recruits KDM6B at the enhancers in response to TGF- $\beta$ , for enhancer transcription<sup>90</sup>. Here we propose a model that, once stimulated by mitogens due to oncogenic activity, KDM6B is recruited to chromatin to maintain the low levels of H3K27me3 at the distal regulatory enhancer regions bound by CTCF and BORIS, which loops and physically interacts with E2F transcription factors that bind at the promoters of target genes, together with associated transcriptional machinery including RNA polymerase II and transcription mediators, driving the expression of *MYCN* and the E2F transcriptome (Figure 8A). When KDM6B is inhibited, the H3K27me3 accumulates at the distal regions and disrupts the assembly of transcriptionally active interaction of promoter-enhancers, leading to the downregulation of *MYCN* and the E2F transcriptome (Figure 8B).

Interestingly, expression of the PRC2 complex, which is a downstream target of pRB-E2F<sup>60,61</sup> and MYCN<sup>28</sup>, was downregulated by KDM6B inhibition, in line with of the decrease of a number of H3K27me3 peaks and de-repression of a tumor suppressive program governed by EZH2<sup>28</sup>. The connection between KDM6B and EZH2 is interesting. Since EZH2 is a downstream target of E2F and MYCN, we assumed the reduction of EZH2 by KDM6B inhibition is through this mechanism. However, considering both proteins are epigenetic modifiers that confer cellular plasticity, we also speculate that cells strive for adaptation to the KDM6B inhibition by suppressing EZH2 in order to counterbalance the net increase of H3K27me3.

Neuroblastoma is a disease that arises as a result of blocked differentiation of neural crest precursors (NCCs) during development<sup>19,20</sup>. EZH2 is required to maintain the undifferentiated state of neuroblastoma<sup>28,91</sup>. Thus, our data and that from other studies indicate that a network composed of MYCN, E2F, PRC2 and KDM6B regulates cell proliferation and differentiation of neuroblastoma (Figure 8C), highlighting the importance of KDM6B in coupling the two essential features of cancer cells. In summary, we have defined a novel chromatin-dependent mechanism of action of KDM6B inhibition that modulates the CDK4/6-pRB-E2F pathway in neuroblastoma. We also demonstrate that E2F target genes can act as biomarkers for sensitivity to KDM6B inhibitors in neuroblastoma and that this may well be predictive for other MYC-driven tumors.

## MATERIALS AND METHODS

### Cell Culture and Reagents

Neuroblastoma cell lines BE2(C) (ATCC), SIMA (DSMZ, Germany), SKNDZ (ATCC), SK-N-AS (ATCC), SK-N-SH (ATCC), IMR32 (ATCC), CHLA20 (COG), NB-1691 (Peter Houghton), HS68 (ATCC) were cultured in standard RPMI media supplemented with 10% FBS (Sigma), 1% L-glutamine (MediaTech), at 37 °C in 5% CO<sub>2</sub>. Colorectal cancer cell lines HCT116, and isogenic p53<sup>-/-</sup> HCT116 cells were kindly provided by Bert Vogelstein (Baltimore, MD), osteosarcoma cell line U2OS, lung cancer cell lines A549 purchased from ATCC, and they were cultured in standard DMEM media supplemented with 10% FCBS, 1% L-glutamine (MediaTech), at 37 °C in 5% CO<sub>2</sub>. Cell lines were validated by short tandem repeat (STR) using Promega PowerPlex 16 HS System once per month. PCR-based method was used for detection of Mycoplasma with LookOut Mycoplasma PCR Detection Kit (Sigma) and JumpStart Taq DNA Polymerase (Sigma) once per month to ensure cells were mycoplasma negative. GSK-J4,



544 Palbociclib, 17-DMAG, JQ-1 were purchased from Selleckchem. KDM5-C70 was purchased from Xcess  
545 Biosciences Inc.

## 546 **AlphaLISA**

547 Materials: GSK J1 is purchased from Tocris (Bristol, United Kingdom, Catalog number 4593). 2,4-  
548 Pyridine Dicarboxylic Acid (2,4-PCA) is purchased from Acros Organics (New Jersey, Catalog number  
549 101860010). JIB-04 is purchased from Sigma-Aldrich (St. Louis, MO, Catalog number SML0808).  
550 Daminozide is purchased from Tocris (Bristol, United Kingdom, MO, Catalog number 4684). AlphaLISA  
551 anti-mIgG acceptor beads from PerkinElmer (Santa Clara, CA, Catalog number AL105C). AlphaLISA  
552 anti-rIgG acceptor beads from PerkinElmer (Santa Clara, CA, Catalog number AL104C). AlphaScreen  
553 Streptavidin-conjugated donor beads from PerkinElmer (Santa Clara, CA, Catalog number 6760002).  
554 Primary antibody 5 from BPS (Catalog number 52140E). Primary antibody 6 from BPS (Catalog number  
555 52140F). Primary antibody 13-4 from BPS (Catalog number 52140M4). Primary antibody 16-2 from BPS  
556 (Catalog number 52140P-2). Primary antibody 17-4 from BPS (Catalog number 52140Q4). Biotinylated  
557 histone H3 peptide substrate (KDM4A) BPS (Catalog number 79841). Biotinylated histone H3 peptide  
558 substrate (KDM5A) BPS (Catalog number 79840). Biotinylated histone H3 peptide substrate (KDM2A)  
559 BPS (Catalog number 79843). Biotinylated histone H3 peptide substrate (KDM6A and KDM6B) BPS  
560 (Catalog number 79841). Biotinylated histone H3 peptide substrate (KDM3A) BPS (Catalog number  
561 79841). 4x HDM Assay Buffer 2 from BPS (Catalog number 52407). 4x HDM Assay Buffer 3 from BPS  
562 (Catalog number 52408). 4x HDM Assay Buffer 4 from BPS (Catalog number 52409). 4x HDM Assay  
563 Buffer 5 from BPS (Catalog number 79847). 4x Detection buffer from BPS (Catalog number 52301).

564 Assay Conditions: All of the enzymatic reactions were conducted in duplicate at room temperature for 60  
565 minutes in a 10 µl mixture containing assay buffer, histone H3 peptide substrate, demethylase enzyme,  
566 and the test compound. These 10 µl reactions were carried out in wells of 384-well Optiplat  
567 (PerkinElmer). The dilution of the control compounds was first performed in 100 % DMSO. Each  
568 intermediate compound dilution (in 100 % DMSO) will then get directly diluted 30x fold into assay buffer  
569 for 3.3x conc (DMSO). Enzyme only and blank only wells have a final DMSO concentration of 1 %.  
570 From this intermediate step, 3 µl of compound is added to 4 µl of demethylase enzyme dilution is  
571 incubated for 30 minutes at room temperature. After this incubation, 3 µl of peptide substrate is added.  
572 The final DMSO concentration is 1 %. After enzymatic reactions, 5 µl of anti-Mouse Acceptor beads  
573 (PerkinElmer, diluted 1:500 with 1x detection buffer) or 5 µl of anti-Rabbit Acceptor beads (PerkinElmer,  
574 diluted 1:500 with 1x detection buffer) and 5 µl of Primary antibody (BPS, diluted 1:200 with 1x detection

575 buffer) were added to the reaction mix. After brief shaking, plate was incubated for 30 minutes. Finally,  
576 10 µl of AlphaScreen Streptavidin-conjugated donor beads (Perkin, diluted 1:125 with 1x detection buffer)  
577 were added. In 30 minutes, the samples were measured in AlphaScreen microplate reader (EnSpire Alpha  
578 2390 Multilabel Reader, PerkinElmer).

579 Data Analysis: Enzyme activity assays were performed in duplicates at each concentration. The A-screen  
580 intensity data were analyzed and compared. In the absence of the compound, the intensity (Ce) in each  
581 data set was defined as 100 % activity. In the absence of enzyme, the intensity (C0) in each data set was  
582 defined as 0 % activity. The percent activity in the presence of each compound was calculated according  
583 to the following equation: % activity = (C-C0)/(Ce-C0), where C = the A-screen intensity in the presence  
584 of the compound. The values of % activity were plotted on a bar graph.

### 585 **SDS-PAGE and Western blotting**

586 For western blotting, samples were mixed with calculated volume of 2X sample buffer (1M TRIS/HCl,  
587 10% SDS, 0.1% bromophenol-blue, 10% b-mercaptoethanol, 10% glycerol), and heated for 25 minutes  
588 at 96°C. Proteins were resolved on SDS-polyacrylamide gels (SDS-PAGE) and transferred onto PVDF  
589 membrane (Immobilon-P, Millipore). After being incubated with the primary antibody, horseradish  
590 peroxidase-(HRP) conjugated secondary antibody (Novex, Life technologies) at 1: 5000 was used for 1  
591 hour incubation. The signals were detected by chemiluminescence (ECL, Thermo scientific). Antibodies  
592 including H3K4me1 (Abcam Cat# ab8895, RRID:AB\_306847), H3K4me3 (RevMAb Biosciences Cat#  
593 31-1226-00, RRID:AB\_2783580), H3K27ac (Active Motif Cat# 39133, RRID:AB\_2561016),  
594 H3K27me3 (Cell Signaling Technology Cat# 9733, RRID:AB\_2616029), CDK4 (Cell Signaling  
595 Technology Cat# 12790, RRID:AB\_2631166), CDK6 (Cell Signaling Technology Cat# 13331,  
596 RRID:AB\_2721897), β-ACTIN (Sigma-Aldrich Cat# A1978, RRID:AB\_476692), GAPDH (Cell  
597 Signaling Technology Cat# 5174, RRID:AB\_10622025), pRB (4H1) (Cell Signaling Technology Cat#  
598 9309, RRID:AB\_823629), MYCN (Cell Signaling Technology Cat# 9405, RRID:AB\_10692664) or  
599 (Santa Cruz Biotechnology Cat# sc-53993, RRID:AB\_831602), C-MYC (Cell Signaling Technology Cat#  
600 13987, RRID:AB\_2631168), KDM6B (Abclonal, A12763), H3K9me3 (Active Motif, 39161),  
601 H3K36me3 (Abcam, ab9050), were used for western blot.

602

### 603 **Crystal Violet Staining**

After removing media, cells were washed with Dulbecco's phosphate buffered saline without calcium or magnesium (DPBS, Lonza) and treated with 4% Formaldehyde in PBS (PFA) for 20 minutes. Once PFA was removed, cells were stained with 0.1% crystal violet stain for 1 hour.

# **Synergy Assay**

BE2C and SK-N-AS cells were seeded in 96-well plates (3,000 cells per well). After 24 hours, cells were treated with GSK-J4 (0, 0.25, 0.5, 1  $\mu$ M, for BE2C, 0, 0.5, 1, 2.5  $\mu$ M for SK-N-AS) and palbociclib (0, 0.25, 0.5, 1.0, 2.0, 4.0  $\mu$ M) or JQ1 (0, 0.0625, 0.125, 0.25, 0.5, 1.0  $\mu$ M) or 17-DMAG (0, 0.0625, 0.125, 0.25, 0.5, 1.0  $\mu$ M) in a 4x6 matrix. Every combination treatment was performed in quadruplicate. Cells were treated for 5 days, and cell viability was determined using the Prestoblu assay (Invitrogen, A-13262). Cell viability for each treatment was normalized against the control group. A Bliss independence model was used to evaluate combination effects. Percentage over the Bliss score index was calculated with the equation  $(A+B)-A \times B$ , in which A and B are the percentage of growth inhibitions induced by agents A and B at a given dose, respectively. The difference between the Bliss expectation and the observed growth inhibition induced by the combination of agent A and B at the same dose is the Bliss excess.

# **Cell viability assay**

BE2C, and CDK4 or CDK6 overexpressing BE2C (BE2C-CDK4-OE, BE2C-CDK6-OE) cells were seeded in 96-well plates at 3,000 cells per well. After 24 hours, cells were treated with GSK-J4 (0, 0.02, 0.04, 0.08, 0.16, 0.3125, 0.625, 1.25, 2.5, 5.0, 10  $\mu$ M) and palbociclib (0, 0.02, 0.04, 0.08, 0.16, 0.3125, 0.625, 1.25, 2.5, 5.0, 10  $\mu$ M). Cells were treated for 5 days. Cell viability was determined using the Prestoblu assay (Invitrogen, A-13262). Cell viability for each treatment was normalized against no treatment well. EC50 was determined with GraphPad Prism equation  $Y=100/(1+10^{((\text{LogEC50}-X) \times \text{HillSlope}))}$ , EC50 is the concentration that gives a 50% response. HillSlope represents the steepness of the curve.

# **Small interfering RNA Transfection**

Small interfering RNAs (siRNA) were transfected into subconfluent cells using Lipofectamine RNAiMax (Invitrogen) according to manufacturer's instructions. Non-Targeting siRNA#1 (Dharmacon, D-001810-0105) used as siRNA control. The siRNA oligos for KDM6B have sequences as follows: KDM6B#1, 5-GGAAUGAGGUGAAGAACGU-3, KDM6B#2, 5-GGAGACCUCGUGUGGAUUA-3, KDM6B#31, 5-



636 GCAUCUAUCUGGAGAGCAA-3, KDM6B#33, 5-GGAAGAGGAACAGCAACA-3. KDM6B-  
637 3'UTR, 5-AGAAAGAACUAUGAGGAAAUU-3.

638

### 639 **CRISPR knockout of Rb1**

640 The Rb1 CRISPR plasmid with gRNA sequence 5-GCTCTGGGTCCTCCTCAGGA-3 (TLCV2-RB1,  
641 Addgene#87836) was purchased from Addgene. Plasmids were maxiprep by using NucleoBond Xtra  
642 EF kits (Takara Bio USA, 740424-50) according to manufacturer's protocol. Lentivirus was produced by  
643 transient transfection of PEI-pro DNA complex (6µg of TLCV2-RB1, 3 µg of 1-lr, 1 µg RTR, 1 µg of  
644 VSVg with 22 ul of PEI pro in 400 µl of DMEM medium) with 5 x 10<sup>6</sup> HEK293T cells in 10 ml complete  
645 medium (DMEM, 100 U/mL penicillin/streptomycin, 1 x L-glutamine and 10% FBS) in a 10 cm dish.  
646 Virus supernatant was collected every 8-12 hours for 3 days, which were passed through a 0.45 µm filter  
647 and concentrated by ultracentrifuge at 28,500 rpm for 1.5 hours at 4°C. The TLCV2-RB1 virus particles  
648 were added to BE2C cells with polybrene to final concentration of 8 µg/ml. Puromycin (2.5 µg/ml in  
649 complete medium) selection were performed in the next day after virus transduction. To generate Rb1  
650 knockout in BE2C, BE2C-Rb1 cells were treated with 1µM of doxycycline for 72 h, then sorted for green  
651 fluorescent protein (GFP) positive cells to enrich for RB1 knockout. The sorted cells were expanded  
652 without doxycycline in RPMI 1640 media (Corning, 10-040-CM) supplemented with 100 U/mL  
653 penicillin/streptomycin (Gibco, 15140122), and 10% FBS (Sigma-Aldrich, F2442).

654

### 655 **Generation of KDM6B, CDK4 and CDK6 overexpressing cell lines**

656 The CDK4 plasmid (pHAGE-CDK4, Addgene#116724) and CDK6 plasmid (pHAGE-CDK6,  
657 Addgene#116725) were purchased from Addgene. The plasmid maxiprep and lentiviral packaging were  
658 followed by the same protocol as described in Rb1 knockout. To overexpress CDK4 and CDK6 in BE2C  
659 cells, the pHAGE-CDK4 or pHAGE-CDK6 viral particles were transduced to BE2C cells and sorted for  
660 green fluorescent protein (GFP) positive ones. To overexpression KDM6B, MSCV-JMJD3  
661 (Addgene#21212) were packaged into retroviral particles, which were transduced into BE2C cells and  
662 selected with puromycin for stable expression.

663

### 664 **RNA-seq and microarray**

665 Total RNA was extracted from cells by using RNeasy Mini Kit (cat. # 74104) from QIAGEN. Paired-end  
666 sequencing was performed using the High-Seq platform with 100bp read length. Reads were aligned to  
667 the human GRCh37-lite using SJCRH's Strongarm pipeline. Counts per gene were obtained using htseq-

count version 0.6.1 with Gencode vM5 level 1 and 2 gene annotations. Counts were normalized with VOOM and analyzed with LIMMA within the R statistical environment. Significance was defined as having a false discovery rate (FDR) <0.05. VOOM normalized counts were analyzed with Gene Set Enrichment Analysis (GSEA)<sup>92</sup>. For Affymetrix microarray, after quality control with Agilent RNA analyzer, RNA was subjected to hybridization using an Affymetrix Clariom S human array. Differential gene expression was analyzed by t-test using the Differential Expression Analysis module at GenePattern server (<http://genepattern.broadinstitute.org/gp/pages/protocols/DiffExp.html>).

### **Assay for Transposase-Accessible Chromatin using sequencing (ATAC-seq)**

Library preparations for ATAC-seq were based on the protocol with minor modifications<sup>47,93</sup>. Briefly, fresh cultured BE2C cells (100,000 per sample) with or without 2.5μM of GSK-J4 treatment were harvested and washed with 150μl cold Dulbecco's Phosphate-Buffered Saline (DPBS) containing protease inhibitor (PI). Nuclei were collected by centrifuging at 500g for 10 minutes at 4°C after cell pellets were resuspended in lysis buffer (10 mM Tris-Cl pH 7.4, 10 mM NaCl, and 3 mM MgCl<sub>2</sub> containing 0.1% NP-40 and PI). Nuclei were incubated with Tn5 transposon enzyme in transposase reaction mix buffer (Illumina) for 30 min at 37°C. DNAs were purified from transposition sample by using Min-Elute PCR purification kit (Qiagen, Valencia, CA) and measured by Qubit. Polymerase chain reaction (PCR) was performed to amplify with High-Fidelity 2X PCR Master Mix [72°C/5mins+ 98 °C /30 s +12 × (98 °C /10 s + 63 °C /30 s + 72 °C /60 s) + 72 °C /5 min]. The libraries were purified using Min-Elute PCR purification kit (Qiagen, Valencia, CA). ATAC-seq libraries followed by pair-end sequencing on HiSeq4000 (Illumina) in the Hartwell Center at St Jude Children's Research Hospital.

### **ATAC-seq data analysis**

2x100bp paired-end reads obtained from all samples were trimming for Nextera adapter by cutadapt(version 1.9, paired-end mode, default parameter with “ -m 25 -O 6 ”)<sup>94</sup> and aligned to human genome hg19(GRCh37-lite) by BWA (version 0.7.12-r1039, default parameter)<sup>95</sup>, duplicated reads were then marked with Picard(version 2.6.0-SNAPSHOT)<sup>96</sup> and only non-duplicated proper paired reads have been kept by samtools (parameter “-q 1 -F 1804” version 1.2)<sup>97</sup>. After adjustment of Tn5 shift (reads were offset were offset by +4 bp for the sense strand and -5 bp for the antisense strand) we separated reads into nucleosome free, mononucleosome, dinucleosome, trinucleosome as described in Buenrostro et.al<sup>98</sup> by fragment size and generated bigwig files by using the center 80bp of fragments and scale to 20M nucleosome free reads. We observed reasonable nucleosome free peaks and pattern of mono-, di-, tri-

nucleosome on IGV (version 2.4.13)<sup>99</sup>. Next we merged each 2 replicates to enhance peak calling on nucleosome free reads by MACS2(version 2.1.1.20160309 default parameters with “--extsize 200 --nomodel ”)<sup>100</sup>, all cell types have more than 20M nucleosome free reads after merge so we consider all important nucleosome free regions were called. To assure the replicability, we first merge peaks from different treatmeans to create a set of reference chromatin accessible regions. We then counted nucleosome free reads from each of samples overlap the reference regions by bedtools (v2.24.0)<sup>101</sup>. We conclude the reproducibility is good since spearman correlation coefficient between replicates are larger than between samples from different groups. To find the differential accessible regions, we first normalized raw nucleosome free reads counts used trimmed mean of M-values normalization method(TMM) and applied Empirical Bayes Statistics test after linear fitting from voom package(R 3.23, edgeR 3.12.1, limma 3.26.9)<sup>102</sup>. FDR-correct p-value 0.05 and fold change > 2 were used as cutoff for differential accessible regions (DARs) while p-value > 0.5 and fold change < 1.05 were used for control regions. To find the Transcription factor enriched for DARs, we scanned the TRANSFAC <sup>103</sup> motif database using FIMO(parameter “--motif-pseudo 0.0001 --thresh 1e-4”) from MEME suite(v4.11.3)<sup>104</sup>, then for each motif, we counted how many DARs or control regions have the motif matches and using Fisher exact test to estimate their enrichment over the background(DAR or control regions don’t have the motif matches).

## CUT&Tag and analysis

CUT&Tag for KDM6B knockdown and GSK-J4 treatment was prepared by following the protocol as described previously (Kaya-Okur et al. 2019 and <https://www.protocols.io/view/bench-top-cut-amp-tag-bcuhiwt6?step=1> ) with minor modifications. Approximately 500,000 BE2C cells were treated with siRNAs (siCtrl or siKDM6B) or compounds (DMSO 0.1% or GSK-J4 2.5μM) for 72 hours, followed by washing with wash buffer (20 mM HEPES pH 7.5; 150 mM NaCl; 0.5 mM Spermidine; 1× Protease inhibitor cocktail). Nuclei were isolated with cold NE1 buffer (20 mM HEPES–KOH, pH 7.9; 10 mM KCl 0.1%; Triton X-100; 20% Glycerol, 0.5 mM Spermidine; 1x Protease Inhibitor) for 10 min on ice. Nuclei were collected by 600 x g centrifuge and resuspended in 1ml washing buffer containing with 10 μL of activated concanavalin A-coated beads (Bangs laboratories, BP531) at RT for 10 min. Bead-bound nuclei were collected with placing tube on magnet stand and removing clear liquid. The nuclei bound with bead were resuspended in 50 μL Dig-150 buffer (20 mM HEPES pH 7.5; 150 mM NaCl; 0.5 mM Spermidine; 1× Protease inhibitor cocktail; 0.05% Digitonin; 2 mM EDTA) and incubated with a 1:50 dilution of H3K4me1 (Abcam, ab8895) and H3K27me3 (CST, 9733S) antibodies overnight at 4 °C. The

unbound primary antibody was removed by placing the tube on the magnet stand and withdrawing the liquid. The primary antibody bound nuclei bead was mixed with 100uL of Dig-150 buffer containing guinea pig anti-Rabbit IgG antibody (Antibodies, ABIN101961) in 1:100 dilution for 1 hour at RT. Beads bound nuclei were washed using the magnet stand 3× for 5 min in 1 mL Dig-150 buffer to remove unbound antibodies. A 1:100 dilution of pA-Tn5 adapter complex was prepared in Dig-300 buffer (20 mM HEPES, pH 7.5, 300 mM NaCl, 0.5 mM Spermidine, 0.05% Digitonin, 1× Protease inhibitor cocktail). After removing the liquid on the magnet stand, 100 µL mixture of pA-Tn5 and Dig- 300 buffer was added to the nuclei bound beads with gentle vortex and incubated at RT for 1 h. After 3× 5 min in 1 mL Dig-300 buffer to remove unbound pA-Tn5 protein, nuclei were resuspended in 250 µL Tagmentation buffer (10 mM MgCl<sub>2</sub> in Dig-300 buffer) and incubated at 37 °C for 1 h. 10 µL of 0.5 M EDTA, 3 µL of 10% SDS and 2.5 µL of 20 mg/mL Proteinase K were added to stop tagmentation and incubated at 55 °C for 1 hour. DNA was then precipitated by phenol/chloroform/isoamylalcohol followed by ethanol precipitation with glycogen and then dissolved in water. Sequencing libraries were prepared using NEBNext HiFi 2× PCR Master Mix (NEB, M0541L) according to the manufacturer's instructions. The PCR products were cleaned up with SPRIselect beads and quantified using Qubit dsDNA HS assay kit (Agilent Technologies). The libraries were sequenced on a HiSeq2500 with paired-end 50-bp reads (Illumina).

Mapping reads and peak calling. The Cut&Tag raw reads were aligned to the human reference genome (hg19) using BWA (version 0.7.12; BWA aln+sampe). Duplicate reads were marked and removed by Picard (version 1.65). Only properly paired uniquely mapped reads with a fragment size of 150bp-2000bp were extracted by samtools (version 1.3.1 parameters used were -q 1 -f 2 -F 1804) for calling peaks and generating bigwig file. Narrow peaks were called by MACS2 (version 2.2.7.1) with parameters of “ -t cut\_tag\_file -q 0.05 -f BED --keep-dup all” for CUT&Tag data). We used SICER (version 1.1, with parameters of redundancy threshold 1, window size 200bp, effective genome fraction 0.86, gap size 600bp, FDR 0.00001 with fragment size defined above) for calling broad enriched regions. Unmapped reads were further aligned to E.Coli genome as a spike-in control to calculate ChIP-Rx scaling factor as described<sup>105,106</sup>. The Cut&Tag library size of each sample was adjusted by E.Coli spike-in scaling factor and then used to normalize the read count for the downstream differential analysis, IGV bigwig and heatmap visualization.

Visualization. We used genomeCoverageBed (BEDtools 2.25.0) to produce genome-wide coverage in BEDGRAPH file and then converted it to a bigwig file by bedGraphToBigWig. The bigwig signals were adjusted by E.Coli spike-in scaling factor and scaled to 15 million reads to allow comparison across samples. To show average of several replicates as a single track in the browser, the bigwig files were

merged to a single average bigwig file using UCSC tools bigWigtoBedGraph, bigWigMerge and bedGraphToBigWig. The Integrated Genomics Viewer (IGV 2.3.82) was used for visual exploration of data. DeepTools (version 2.3)<sup>107</sup> was used to plot heatmap.

Differential analysis. Cut&Tag raw read counts were reported for each region/each sample using BEDtools 2.25.0. Raw read counts were Voom normalized and statistically contrasted using the R (version 3.5.1) packages limma and edgeR (version 3.16.5) for CPM calculation and differential analysis. An empirical Bayes fit was applied to contrast treated samples to control samples and to generate log fold changes, p values and false discovery rates for each peak region.

Peak overlap and annotation. Peak regions were defined to be the union of peak intervals in replicates from control or treated cells respectively. For peak overlap analysis, mergeBed (BEDtools version 2.25.0) was used to combine overlapping regions from multiple peak sets into a new region and then a custom script was used to summarize common or distinct peaks and visualize in a venn diagram. Promoter regions was defined as the regions 1.0 kb upstream and 1.0 kb downstream of the transcription start sites based on the human RefSeq annotation (hg19). Genomic feature annotation of peaks was done by annotatePeaks.pl, a program from the HOMER suite (v4.8.3, <http://homer.salk.edu/homer/>).

Motif analysis. Adjacent histone mark peaks (within a distance of 100bp) from both control and treated samples were merged first and then separated to 3 subgroups including control-only, treatment-only and shared peaks (at least 1bp overlap) using Bedtools (version 2.25.0). The regions of peak center +/- 100 bp were used for HOMER known motif search. Top ten most significant motifs from each sub-group were visualized as a heatmap.

## Hi-C data mining

To view the 3D chromatin conformation of *MYCN* and *E2F8* gene in BE2C, we mined the Hi-C data, of BE2C, KELLY and SK-N-AS cells, which were downloaded from St Jude Cloud (<https://www.stjude.cloud/>)<sup>108</sup>. The Arc TRAC data showing the chromatin interactions, which were generated from Jurkat ChIA-PET SMC1 (Mango), were downloaded from St Jude Protein Paint program under St Jude Cloud (<https://proteinpaint.stjude.org/>).

## Library of Integrated Network-based Cellular Signatures (LINCS) analysis

We had two sets of gene expression data: microarray and RNA-seq for siKDM6B and GSK-J4 treatment. While the pathway analysis showed very similar results for each, we used them in different purposes. Because Lincs used a limited number of genes in characterizing chemical compounds signatures, we chose

our microarray data to compare since RNA-seq data gave rise to a large amount of gene expression data that were not covered by Lincs chemical signatures. We first identify differentially expressed genes in microarray data using GenePattern program (<https://cloud.genepattern.org/gp/pages/index.jsf>). Then we chose the downregulated genes (with logFC  $\geq 0.7$ ) by KDM6B knockdown or GSK-J4 treatment to compare with the chemical signatures in LINCS database (<http://www.lincsproject.org/LINCS/tools>). The datasets from LINCS L1000 Chem Pert down were downloaded and analyzed using PRISM program.

### **The Cancer Therapeutics Response Portal (CTRP) analysis**

Cancer Therapeutic Response Portal (<https://portals.broadinstitute.org/ctrp.v2.1/>) correlated the sensitivity patterns of 481 compounds including GSK-J4 with 19,000 basal transcript levels across different human cancer cell lines and identified selective outlier transcripts<sup>44,45</sup>, which allowed to interrogate whether KDM6B inhibitor was correlated with specific transcripts. We chose the features that show the correlation of drug sensitivity with gene expression or copy number of quired genes such as E2F8.

### **Kaplan-Meier analysis**

A 149-gene signature commonly downregulated by GSK-J4 in BE2C and three other neuroblastoma cell lines (IMR5, LAN5 and SK-N-FI)<sup>43</sup> was uploaded into R2 genomics analysis and visualization program (<https://hgserver1.amc.nl/cgi-bin/r2/main.cgi>) to find the differentially expressed genes in high-risk neuroblastoma in dataset (GSE49710) that has 498 cases, followed by k-means cluster analysis. The 4 clusters were stored as track for Kaplan-Meier curve analysis using Log-Rank method for event-free survival and overall survival.

### **Statistical analysis**

To determine statistical significance, the unpaired, two-tailed Student *t* test was calculated using the *t* test calculator available on GraphPad Prism 8.0 software. A *p* value of less than 0.05 was considered statistically significant.

### **Data accessibility**

Super series GSE149539 includes 3 datasets.

<https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE149539&token=ehozmooupbajlaf>



GSE182884 [CUT&TAG]  
KDM6B regulates an CDK4/6-pRB-E2F transcriptome that is correlated with GSK-J4 sensitivity  
GSE149519 [ATAC-seq]  
KDM6B regulates an CDK4/6-pRB-E2F transcriptome that is correlated with GSK-J4 sensitivity  
GSE149537 [RNA-seq]  
KDM6B regulates an CDK4/6-pRB-E2F transcriptome that is correlated with GSK-J4 sensitivity

## Acknowledgments

This work was partly supported by American Cancer Society-Research Scholar (130421-RSG-17-071-01-TBG, Jun Yang) and National Cancer Institute (1R01CA229739-01, Jun Yang). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

## Contributions

Alexandra D'Oto, Jie Fang, Shivendra Singh, Anoushka Mullasseril, Victoria Jones, Xinyu von Buttlar, Bailey Cooke, Dongli Hu, Ahmed Abu-Zaid performed experiments. Beisi Xu and Hongjian Jin analyzed sequencing data. Jun Yang and Andrew M Davidoff conceived the project. Jun Yang wrote the manuscript with input from Jason Shohet, Andrew J Murphy and Andrew M Davidoff.

## References

- 1 Agger, K. *et al.* UTX and JMJD3 are histone H3K27 demethylases involved in HOX gene regulation and development. *Nature* **449**, 731-734, doi:10.1038/nature06145 (2007).
- 2 De Santa, F. *et al.* The histone H3 lysine-27 demethylase Jmjd3 links inflammation to inhibition of polycomb-mediated gene silencing. *Cell* **130**, 1083-1094, doi:10.1016/j.cell.2007.08.019 (2007).
- 3 Hong, S. *et al.* Identification of JmjdC domain-containing UTX and JMJD3 as histone H3 lysine 27 demethylases. *Proc Natl Acad Sci U S A* **104**, 18439-18444, doi:10.1073/pnas.0707292104 (2007).
- 4 Xiang, Y. *et al.* JMJD3 is a histone H3K27 demethylase. *Cell Res* **17**, 850-857, doi:10.1038/cr.2007.83 (2007).
- 5 Margueron, R. *et al.* Ezh1 and Ezh2 maintain repressive chromatin through different mechanisms. *Mol Cell* **32**, 503-518, doi:10.1016/j.molcel.2008.11.004 (2008).
- 6 Walport, L. J. *et al.* Human UTY(KDM6C) is a male-specific N-methyl lysyl demethylase. *J Biol Chem* **289**, 18302-18313, doi:10.1074/jbc.M114.555052 (2014).

- 7 Kandoth, C. *et al.* Mutational landscape and significance across 12 major cancer types. *Nature* **502**, 333-339, doi:10.1038/nature12634 (2013).
- 8 Huether, R. *et al.* The landscape of somatic mutations in epigenetic regulators across 1,000 paediatric cancer genomes. *Nat Commun* **5**, 3630, doi:10.1038/ncomms4630 (2014).
- 9 Agger, K. *et al.* The H3K27me3 demethylase JMJD3 contributes to the activation of the INK4A-ARF locus in response to oncogene- and stress-induced senescence. *Genes Dev* **23**, 1171-1176, doi:10.1101/gad.510809 (2009).
- 10 Barradas, M. *et al.* Histone demethylase JMJD3 contributes to epigenetic control of INK4a/ARF by oncogenic RAS. *Genes Dev* **23**, 1177-1182, doi:10.1101/gad.511109 (2009).
- 11 Ene, C. I. *et al.* Histone demethylase Jumonji D3 (JMJD3) as a tumor suppressor by regulating p53 protein nuclear stabilization. *PLoS One* **7**, e51407, doi:10.1371/journal.pone.0051407 (2012).
- 12 Yamamoto, K. *et al.* Loss of histone demethylase KDM6B enhances aggressiveness of pancreatic cancer through downregulation of C/EBPalpha. *Carcinogenesis* **35**, 2404-2414, doi:10.1093/carcin/bgu136 (2014).
- 13 Arcipowski, K. M., Martinez, C. A. & Ntziachristos, P. Histone demethylases in physiology and cancer: a tale of two enzymes, JMJD3 and UTX. *Curr Opin Genet Dev* **36**, 59-67, doi:10.1016/j.gde.2016.03.010 (2016).
- 14 Ntziachristos, P. *et al.* Contrasting roles of histone 3 lysine 27 demethylases in acute lymphoblastic leukaemia. *Nature* **514**, 513-517, doi:10.1038/nature13605 (2014).
- 15 Ohguchi, H. *et al.* KDM6B modulates MAPK pathway mediating multiple myeloma cell growth and survival. *Leukemia*, doi:10.1038/leu.2017.141 (2017).
- 16 Sherry-Lynes, M. M., Sengupta, S., Kulkarni, S. & Cochran, B. H. Regulation of the JMJD3 (KDM6B) histone demethylase in glioblastoma stem cells by STAT3. *PLoS One* **12**, e0174775, doi:10.1371/journal.pone.0174775 (2017).
- 17 Tang, B. *et al.* Aberrant JMJD3 Expression Upregulates Slug to Promote Migration, Invasion, and Stem Cell-Like Behaviors in Hepatocellular Carcinoma. *Cancer Res* **76**, 6520-6532, doi:10.1158/0008-5472.CAN-15-3029 (2016).
- 18 Dalvi, M. P. *et al.* Taxane-Platin-Resistant Lung Cancers Co-develop Hypersensitivity to JumonjiC Demethylase Inhibitors. *Cell Rep* **19**, 1669-1684, doi:10.1016/j.celrep.2017.04.077 (2017).
- 19 Maris, J. M. Recent advances in neuroblastoma. *N Engl J Med* **362**, 2202-2211, doi:10.1056/NEJMra0804577 (2010).
- 20 Cheung, N. K. & Dyer, M. A. Neuroblastoma: developmental biology, cancer genomics and immunotherapy. *Nat Rev Cancer* **13**, 397-411, doi:10.1038/nrc3526 (2013).
- 21 Bosse, K. R. & Maris, J. M. Advances in the translational genomics of neuroblastoma: From improving risk stratification and revealing novel biology to identifying actionable genomic alterations. *Cancer*, doi:10.1002/cncr.29706 (2015).



- 22 Gustafson, W. C. & Weiss, W. A. Myc proteins as therapeutic targets. *Oncogene* **29**, 1249-1259, doi:10.1038/onc.2009.512 (2010).
- 23 Chipumuro, E. *et al.* CDK7 inhibition suppresses super-enhancer-linked oncogenic transcription in MYCN-driven cancer. *Cell* **159**, 1126-1139, doi:10.1016/j.cell.2014.10.024 (2014).
- 24 Puissant, A. *et al.* Targeting MYCN in neuroblastoma by BET bromodomain inhibition. *Cancer Discov* **3**, 308-323, doi:10.1158/2159-8290.CD-12-0418 (2013).
- 25 He, S., Liu, Z., Oh, D. Y. & Thiele, C. J. MYCN and the epigenome. *Front Oncol* **3**, 1, doi:10.3389/fonc.2013.00001 (2013).
- 26 Yang, J. *et al.* The role of histone demethylase KDM4B in Myc signaling in neuroblastoma. *J Natl Cancer Inst* **107**, djv080, doi:10.1093/jnci/djv080 (2015).
- 27 Yang, J. *et al.* Targeting Histone Demethylases in MYC-Driven Neuroblastomas with Ciclopirox. *Cancer Res* **77**, 4626-4638, doi:10.1158/0008-5472.CAN-16-0826 (2017).
- 28 Chen, L. *et al.* CRISPR-Cas9 screen reveals a MYCN-amplified neuroblastoma dependency on EZH2. *J Clin Invest* **128**, 446-462, doi:10.1172/JCI90793 (2018).
- 29 Matthay, K. K. *et al.* Neuroblastoma. *Nat Rev Dis Primers* **2**, 16078, doi:10.1038/nrdp.2016.78 (2016).
- 30 Molenaar, J. J. *et al.* Sequencing of neuroblastoma identifies chromothripsis and defects in neuritogenesis genes. *Nature* **483**, 589-593, doi:10.1038/nature10910 (2012).
- 31 Fix, A. *et al.* Characterization of amplicons in neuroblastoma: high-resolution mapping using DNA microarrays, relationship with outcome, and identification of overexpressed genes. *Genes Chromosomes Cancer* **47**, 819-834, doi:10.1002/gcc.20583 (2008).
- 32 Lastowska, M. *et al.* Identification of candidate genes involved in neuroblastoma progression by combining genomic and expression microarrays with survival data. *Oncogene* **26**, 7432-7444, doi:10.1038/sj.onc.1210552 (2007).
- 33 Bannister, A. J. & Kouzarides, T. Regulation of chromatin by histone modifications. *Cell Res* **21**, 381-395, doi:10.1038/cr.2011.22 (2011).
- 34 Whyte, W. A. *et al.* Master transcription factors and mediator establish super-enhancers at key cell identity genes. *Cell* **153**, 307-319, doi:10.1016/j.cell.2013.03.035 (2013).
- 35 Pott, S. & Lieb, J. D. What are super-enhancers? *Nat Genet* **47**, 8-12, doi:10.1038/ng.3167 (2015).
- 36 Dyson, N. J. RB1: a prototype tumor suppressor and an enigma. *Genes Dev* **30**, 1492-1502, doi:10.1101/gad.282145.116 (2016).
- 37 Thurlings, I. & de Bruin, A. E2F Transcription Factors Control the Roller Coaster Ride of Cell Cycle Gene Expression. *Methods Mol Biol* **1342**, 71-88, doi:10.1007/978-1-4939-2957-3\_4 (2016).
- 38 Strieder, V. & Lutz, W. E2F proteins regulate MYCN expression in neuroblastomas. *J Biol Chem* **278**, 2983-2989, doi:10.1074/jbc.M207596200 (2003).

958 39 Ishida, S., Shudo, K., Takada, S. & Koike, K. A direct role of transcription factor  
959 E2F in c-myc gene expression during granulocytic and macrophage-like  
960 differentiation of HL60 cells. *Cell Growth Differ* **6**, 229-237 (1995).  
961 40 Kruidenier, L. *et al.* A selective jumonji H3K27 demethylase inhibitor  
962 modulates the proinflammatory macrophage response. *Nature* **488**, 404-408,  
963 doi:10.1038/nature11262 (2012).  
964 41 Heinemann, B. *et al.* Inhibition of demethylases by GSK-J1/J4. *Nature* **514**,  
965 E1-2, doi:10.1038/nature13688 (2014).  
966 42 Johansson, C. *et al.* Structural analysis of human KDM5B guides histone  
967 demethylase inhibitor development. *Nat Chem Biol* **12**, 539-545,  
968 doi:10.1038/nchembio.2087 (2016).  
969 43 Lochmann, T. L. *et al.* Targeted inhibition of histone H3K27 demethylation is  
970 effective in high-risk neuroblastoma. *Sci Transl Med* **10**,  
971 doi:10.1126/scitranslmed.aao4680 (2018).  
972 44 Rees, M. G. *et al.* Correlating chemical sensitivity and basal gene expression  
973 reveals mechanism of action. *Nat Chem Biol* **12**, 109-116,  
974 doi:10.1038/nchembio.1986 (2016).  
975 45 Seashore-Ludlow, B. *et al.* Harnessing Connectivity in a Large-Scale Small-  
976 Molecule Sensitivity Dataset. *Cancer Discov* **5**, 1210-1223, doi:10.1158/2159-  
977 8290.CD-15-0235 (2015).  
978 46 Bertoli, C., Skotheim, J. M. & de Bruin, R. A. Control of cell cycle transcription  
979 during G1 and S phases. *Nat Rev Mol Cell Biol* **14**, 518-528,  
980 doi:10.1038/nrm3629 (2013).  
981 47 Buenrostro, J. D., Wu, B., Chang, H. Y. & Greenleaf, W. J. ATAC-seq: A Method  
982 for Assaying Chromatin Accessibility Genome-Wide. *Curr Protoc Mol Biol*  
983 **109**, 21 29 21-21 29 29, doi:10.1002/0471142727.mb2129s109 (2015).  
984 48 Hoxhaj, G. & Manning, B. D. The PI3K-AKT network at the interface of  
985 oncogenic signalling and cancer metabolism. *Nat Rev Cancer* **20**, 74-88,  
986 doi:10.1038/s41568-019-0216-7 (2020).  
987 49 Chaussepied, M. & Ginsberg, D. Transcriptional regulation of AKT activation  
988 by E2F. *Mol Cell* **16**, 831-837, doi:10.1016/j.molcel.2004.11.003 (2004).  
989 50 Kaya-Okur, H. S., Janssens, D. H., Henikoff, J. G., Ahmad, K. & Henikoff, S.  
990 Efficient low-cost chromatin profiling with CUT&Tag. *Nat Protoc* **15**, 3264-  
991 3283, doi:10.1038/s41596-020-0373-x (2020).  
992 51 Helmsauer, K. *et al.* Enhancer hijacking determines extrachromosomal  
993 circular MYCN amplicon architecture in neuroblastoma. *Nat Commun* **11**,  
994 5823, doi:10.1038/s41467-020-19452-y (2020).  
995 52 Phillips, J. E. & Corces, V. G. CTCF: master weaver of the genome. *Cell* **137**,  
996 1194-1211, doi:10.1016/j.cell.2009.06.001 (2009).  
997 53 Wendt, K. S. *et al.* Cohesin mediates transcriptional insulation by CCCTC-  
998 binding factor. *Nature* **451**, 796-801, doi:10.1038/nature06634 (2008).  
999 54 Debruyne, D. N. *et al.* BORIS promotes chromatin regulatory interactions in  
1000 treatment-resistant cancer cells. *Nature* **572**, 676-680, doi:10.1038/s41586-  
1001 019-1472-0 (2019).  
1002 55 Local, A. *et al.* Identification of H3K4me1-associated proteins at mammalian  
1003 enhancers. *Nat Genet* **50**, 73-82, doi:10.1038/s41588-017-0015-6 (2018).


- 56 Kagey, M. H. *et al.* Mediator and cohesin connect gene expression and chromatin architecture. *Nature* **467**, 430-435, doi:10.1038/nature09380 (2010).
- 57 Kim, S. I., Bultman, S. J., Kiefer, C. M., Dean, A. & Bresnick, E. H. BRG1 requirement for long-range interaction of a locus control region with a downstream promoter. *Proc Natl Acad Sci U S A* **106**, 2259-2264, doi:10.1073/pnas.0806420106 (2009).
- 58 Beagrie, R. A. *et al.* Complex multi-enhancer contacts captured by genome architecture mapping. *Nature* **543**, 519-524, doi:10.1038/nature21411 (2017).
- 59 Rao, S. S. *et al.* A 3D map of the human genome at kilobase resolution reveals principles of chromatin looping. *Cell* **159**, 1665-1680, doi:10.1016/j.cell.2014.11.021 (2014).
- 60 Bracken, A. P. *et al.* EZH2 is downstream of the pRB-E2F pathway, essential for proliferation and amplified in cancer. *EMBO J* **22**, 5323-5335, doi:10.1093/emboj/cdg542 (2003).
- 61 Lee, S. R. *et al.* Activation of EZH2 and SUZ12 Regulated by E2F1 Predicts the Disease Progression and Aggressive Characteristics of Bladder Cancer. *Clin Cancer Res* **21**, 5391-5403, doi:10.1158/1078-0432.CCR-14-2680 (2015).
- 62 Keenan, A. B. *et al.* The Library of Integrated Network-Based Cellular Signatures NIH Program: System-Level Cataloging of Human Cells Response to Perturbations. *Cell Syst* **6**, 13-24, doi:10.1016/j.cels.2017.11.001 (2018).
- 63 Filippakopoulos, P. *et al.* Selective inhibition of BET bromodomains. *Nature* **468**, 1067-1073, doi:10.1038/nature09504 (2010).
- 64 Sherr, C. J., Beach, D. & Shapiro, G. I. Targeting CDK4 and CDK6: From Discovery to Therapy. *Cancer Discov* **6**, 353-367, doi:10.1158/2159-8290.CD-15-0894 (2016).
- 65 Alvarez-Fernandez, M. & Malumbres, M. Mechanisms of Sensitivity and Resistance to CDK4/6 Inhibition. *Cancer Cell* **37**, 514-529, doi:10.1016/j.ccell.2020.03.010 (2020).
- 66 Klein, M. E., Kovatcheva, M., Davis, L. E., Tap, W. D. & Koff, A. CDK4/6 Inhibitors: The Mechanism of Action May Not Be as Simple as Once Thought. *Cancer Cell* **34**, 9-20, doi:10.1016/j.ccell.2018.03.023 (2018).
- 67 Yang, L. *et al.* Histone demethylase KDM6B has an anti-tumorigenic function in neuroblastoma by promoting differentiation. *Oncogenesis* **8**, 3, doi:10.1038/s41389-018-0112-0 (2019).
- 68 Hashizume, R. *et al.* Pharmacologic inhibition of histone demethylation as a therapy for pediatric brainstem glioma. *Nat Med* **20**, 1394-1396, doi:10.1038/nm.3716 (2014).
- 69 Morozov, V. M., Li, Y., Clowers, M. M. & Ishov, A. M. Inhibitor of H3K27 demethylase JMJD3/UTX GSK-J4 is a potential therapeutic option for castration resistant prostate cancer. *Oncotarget* **8**, 62131-62142, doi:10.18632/oncotarget.19100 (2017).
- 70 Mathur, R. *et al.* Inhibition of demethylase KDM6B sensitizes diffuse large B-cell lymphoma to chemotherapeutic drugs. *Haematologica* **102**, 373-380, doi:10.3324/haematol.2016.144964 (2017).

1050 71 Hong, B. J. *et al.* Oncogenic KRAS Sensitizes Lung Adenocarcinoma to GSK-J4-  
1051 Induced Metabolic and Oxidative Stress. *Cancer Res* **79**, 5849-5859,  
1052 doi:10.1158/0008-5472.CAN-18-3511 (2019).  
1053 72 Hnisz, D. *et al.* Super-enhancers in the control of cell identity and disease. *Cell*  
1054 **155**, 934-947, doi:10.1016/j.cell.2013.09.053 (2013).  
1055 73 Leone, G. *et al.* Myc requires distinct E2F activities to induce S phase and  
1056 apoptosis. *Mol Cell* **8**, 105-113, doi:10.1016/s1097-2765(01)00275-1 (2001).  
1057 74 Chen, X. *et al.* Integration of external signaling pathways with the core  
1058 transcriptional network in embryonic stem cells. *Cell* **133**, 1106-1117,  
1059 doi:10.1016/j.cell.2008.04.043 (2008).  
1060 75 Sherr, C. J. & McCormick, F. The RB and p53 pathways in cancer. *Cancer Cell* **2**,  
1061 103-112, doi:10.1016/s1535-6108(02)00102-2 (2002).  
1062 76 Dick, F. A., Goodrich, D. W., Sage, J. & Dyson, N. J. Non-canonical functions of  
1063 the RB protein in cancer. *Nat Rev Cancer* **18**, 442-451, doi:10.1038/s41568-  
1064 018-0008-5 (2018).  
1065 77 Easton, J., Wei, T., Lahti, J. M. & Kidd, V. J. Disruption of the cyclin D/cyclin-  
1066 dependent kinase/INK4/retinoblastoma protein regulatory pathway in  
1067 human neuroblastoma. *Cancer Res* **58**, 2624-2632 (1998).  
1068 78 Krasnoselsky, A. L. *et al.* Altered expression of cell cycle genes distinguishes  
1069 aggressive neuroblastoma. *Oncogene* **24**, 1533-1541,  
1070 doi:10.1038/sj.onc.1208341 (2005).  
1071 79 Molenaar, J. J. *et al.* Copy number defects of G1-cell cycle genes in  
1072 neuroblastoma are frequent and correlate with high expression of E2F target  
1073 genes and a poor prognosis. *Genes Chromosomes Cancer* **51**, 10-19,  
1074 doi:10.1002/gcc.20926 (2012).  
1075 80 Mosse, Y. P. *et al.* Neuroblastomas have distinct genomic DNA profiles that  
1076 predict clinical phenotype and regional gene expression. *Genes Chromosomes*  
1077 *Cancer* **46**, 936-949, doi:10.1002/gcc.20477 (2007).  
1078 81 Mosse, Y. P. *et al.* High-resolution detection and mapping of genomic DNA  
1079 alterations in neuroblastoma. *Genes Chromosomes Cancer* **43**, 390-403,  
1080 doi:10.1002/gcc.20198 (2005).  
1081 82 Molenaar, J. J. *et al.* Cyclin D1 and CDK4 activity contribute to the  
1082 undifferentiated phenotype in neuroblastoma. *Cancer Res* **68**, 2599-2609,  
1083 doi:10.1158/0008-5472.CAN-07-5032 (2008).  
1084 83 Rader, J. *et al.* Dual CDK4/CDK6 inhibition induces cell-cycle arrest and  
1085 senescence in neuroblastoma. *Clin Cancer Res* **19**, 6173-6182,  
1086 doi:10.1158/1078-0432.CCR-13-1675 (2013).  
1087 84 Lee, M. G. *et al.* Demethylation of H3K27 regulates polycomb recruitment and  
1088 H2A ubiquitination. *Science* **318**, 447-450, doi:10.1126/science.1149042  
1089 (2007).  
1090 85 Kim, J. H. *et al.* UTX and MLL4 coordinately regulate transcriptional programs  
1091 for cell proliferation and invasiveness in breast cancer cells. *Cancer Res* **74**,  
1092 1705-1717, doi:10.1158/0008-5472.CAN-13-1896 (2014).  
1093 86 Wong, A. S. *et al.* Multiplexed barcoded CRISPR-Cas9 screening enabled by  
1094 CombiGEM. *Proc Natl Acad Sci U S A* **113**, 2544-2549,  
1095 doi:10.1073/pnas.1517883113 (2016).



- 87 Yan, J. *et al.* Histone H3 lysine 4 monomethylation modulates long-range chromatin interactions at enhancers. *Cell Res* **28**, 204-220, doi:10.1038/cr.2018.1 (2018).
- 88 Vernimmen, D. *et al.* Polycomb eviction as a new distant enhancer function. *Genes Dev* **25**, 1583-1588, doi:10.1101/gad.16985411 (2011).
- 89 Kartikasari, A. E. *et al.* The histone demethylase Jmjd3 sequentially associates with the transcription factors Tbx3 and Eomes to drive endoderm differentiation. *EMBO J* **32**, 1393-1408, doi:10.1038/emboj.2013.78 (2013).
- 90 Fueyo, R. *et al.* Lineage specific transcription factors and epigenetic regulators mediate TGFbeta-dependent enhancer activation. *Nucleic Acids Res* **46**, 3351-3365, doi:10.1093/nar/gky093 (2018).
- 91 Li, Z. *et al.* EZH2 regulates neuroblastoma cell differentiation via NTRK1 promoter epigenetic modifications. *Oncogene* **37**, 2714-2727, doi:10.1038/s41388-018-0133-3 (2018).
- 92 Subramanian, A. *et al.* Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. *Proc Natl Acad Sci U S A* **102**, 15545-15550, doi:10.1073/pnas.0506580102 (2005).
- 93 Buenrostro, J. D., Giresi, P. G., Zaba, L. C., Chang, H. Y. & Greenleaf, W. J. Transposition of native chromatin for fast and sensitive epigenomic profiling of open chromatin, DNA-binding proteins and nucleosome position. *Nat Methods* **10**, 1213-1218, doi:10.1038/nmeth.2688 (2013).
- 94 Martin, M. Cutadapt removes adapter sequences from high-throughput sequencing reads. *EMBnet.journal* **17**, pp.-10-12 (2011).
- 95 Li, H. & Durbin, R. Fast and accurate short read alignment with Burrows-Wheeler transform. *Bioinformatics* **25**, 1754-1760, doi:10.1093/bioinformatics/btp324 (2009).
- 96 Tischler, G. & Leonard, S. biobambam: tools for read pair collation based algorithms on BAM files. *Source Code for Biology and Medicine* **9**, 13, doi:10.1186/1751-0473-9-13 (2014).
- 97 Li, H. *et al.* The Sequence Alignment/Map format and SAMtools. *Bioinformatics* **25**, 2078-2079, doi:10.1093/bioinformatics/btp352 (2009).
- 98 Buenrostro, J. D., Giresi, P. G., Zaba, L. C., Chang, H. Y. & Greenleaf, W. J. Transposition of native chromatin for fast and sensitive epigenomic profiling of open chromatin, DNA-binding proteins and nucleosome position. *Nature Methods* **10**, 1213-1218, doi:10.1038/nmeth.2688 (2013).
- 99 Robinson, J. T. *et al.* Integrative genomics viewer. *Nature Biotechnology* **29**, 24-26, doi:10.1038/nbt.1754 (2011).
- 100 Zhang, Y. *et al.* Model-based Analysis of ChIP-Seq (MACS). *Genome Biology* **9**, R137, doi:10.1186/gb-2008-9-9-r137 (2008).
- 101 Quinlan, A. R. & Hall, I. M. BEDTools: a flexible suite of utilities for comparing genomic features. *Bioinformatics* **26**, 841-842, doi:10.1093/bioinformatics/btq033 (2010).
- 102 Law, C. W., Chen, Y., Shi, W. & Smyth, G. K. voom: precision weights unlock linear model analysis tools for RNA-seq read counts. *Genome Biology* **15**, R29, doi:10.1186/gb-2014-15-2-r29 (2014).
- 103 Matys, V. *et al.* TRANSFAC and its module TRANSCompel: transcriptional gene regulation in eukaryotes. *Nucleic Acids Res* **34**, D108 - 110 (2006).

- 104 Bailey, T. L. *et al.* MEME SUITE: tools for motif discovery and searching.  
*Nucleic Acids Res* **37**, W202-208, doi:10.1093/nar/gkp335 (2009).
- 105 Skene, P. J. & Henikoff, S. An efficient targeted nuclease strategy for high-  
resolution mapping of DNA binding sites. *Elife* **6**, doi:10.7554/eLife.21856  
(2017).
- 106 Orlando, D. A. *et al.* Quantitative ChIP-Seq normalization reveals global  
modulation of the epigenome. *Cell Rep* **9**, 1163-1170,  
doi:10.1016/j.celrep.2014.10.018 (2014).
- 107 Ramirez, F. *et al.* deepTools2: a next generation web server for deep-  
sequencing data analysis. *Nucleic Acids Res* **44**, W160-165,  
doi:10.1093/nar/gkw257 (2016).
- 108 McLeod, C. *et al.* St. Jude Cloud: A Pediatric Cancer Genomic Data-Sharing  
Ecosystem. *Cancer Discov* **11**, 1082-1099, doi:10.1158/2159-8290.CD-20-  
1230 (2021).
- 109 Zeid, R. *et al.* Enhancer invasion shapes MYCN-dependent transcriptional  
amplification in neuroblastoma. *Nat Genet* **50**, 515-523,  
doi:10.1038/s41588-018-0044-9 (2018).



**Figure 1. KDM6B is marked with a highly active epigenetic landscape and highly expressed in neuroblastoma and regulates MYC expression.**

**(A-C)** The expression of KDM6B, KDM6A and UTY in normal human trunk neural crest (GSE14340) and 4 different neuroblastoma cohorts (Versteeg GSE16476, Delattre GSE14880, Hiyama GSE16237, Lastowska GSE13136). Y-axis represents the normalized log2 expression value. \*\*\*p<0.001, student t test

**(D-F)** The expression of KDM6B, KDM6A and UTY in 3 different neuroblastoma RNA-seq cohorts. The RNA-seq data of St Jude was downloaded from <https://pecan.stjude.cloud>. The RNA-seq data of TARGET and SEQC datasets were downloaded from R2 (<https://hgserver1.amc.nl/cgi-bin/r2/main.cgi>). Y-axis represents the Fragment Per Kilobase of transcript per Million (FPKM) mapped reads.

**(G)** The epigenetic landscapes consisting of histone marks and transcription factor binding distinguish KDM6B from KDM6A in primary neuroblastoma tissues with MYCN amplification or without MYCN amplification ([https://pecan.stjude.cloud/proteinpaint/study/mycn\\_nbl\\_2018](https://pecan.stjude.cloud/proteinpaint/study/mycn_nbl_2018)).

**(H)** Crystal violet staining of colonies after BE2C and SKNAS cells were transfected with four different siRNA oligos to knockdown KDM6B for 7 days. siCtrl = siRNA control oligo, NT= no treatment.


**(I)** Western blot analysis with indicated antibodies to assess MYCN or C-MYC expression after 3-day transfection of 4 different siRNA to knockdown KDM6B in BE2C and SKNAS.

**(J)** BE2C and MSCV-KDM6B overexpressing (KDM6B-OE) BE2C cells were transfected with siRNA control (siCtrl) and siRNA targeting the endogenous 3' untranslated region (3'UTR) of KDM6B (siKDM6B-3'UTR). 4 days later, cells were stained with crystal violet.

**(K)** Quantification of cell density of each group (n=3) using imageJ. P-value calculated using student t test.

**(L)** BE2C and MSCV-KDM6B overexpressing (KDM6B-OE) BE2C cells were transfected with siRNA control (siCtrl) and siRNA siKDM6B-3'UTR. 2 days later, cells were subject to immunoblotting with indicated antibodies.





1190 **Figure 2. KDM6B predominantly regulates the pRB-E2F pathway.**


1191 **(A)** Quantitative comparison of all chemical and genetic perturbation gene sets ( $n = 3403$ ) from the  
 1192 MSigDB by gene set enrichment analysis (GSEA) for increased (left) and reduced (right) expression of  
 1193 global genes caused by KDM6B knockdown. Data are presented as a scatterplot of normalized p  
 1194 value/false discovery q value vs normalized enrichment score (NES) for each evaluated gene set. The gene  
 1195 sets circled in red color indicate cell cycle, pRB-E2F and MYC pathway gene sets.

1196 **(B)** Two examples of GSEA show that genes downregulated by depletion of KDM6B are enriched with  
 1197 Rb1 knockout and E2F targets.

1198 **(C)** Heatmap shows the gene list from the E2F targets (B).

1199 **(D-F)** Similar analysis for GSK-J4 treatment as shown in (A-C).

1200



### **Figure 3. Chemogenetic data show E2F gene signature is correlated with sensitivity of GSK-J4.**

**(A)** The Pearson correlation Z-score for each tested compound with E2F8 expression, which was extracted from The Cancer Therapeutics Response Portal (CTRP). The correlation of GSK-J4 and E2F8 ranked on the top with  $R=-0.626$ ,  $Z\text{-score}=-4.56$ .


**(B)** The plot of E2F8 expression and GSK-J4 sensitivity for each tested cell line. The y-axis represents the transcript expression levels of E2F8 in each cell line. The x-axis represents the drug response metrics (area under curve, AUC) to GSK-J4. The lower the AUC, the more sensitive to GSK-J4. The circled group A and B populations are arbitrarily chosen as GSK-J4 sensitive vs resistant.

**(C)** Quantitative comparison of all chemical and genetic perturbation gene sets ( $n = 3403$ ) from the MSigDB by gene set enrichment analysis (GSEA) for GSK-J4 sensitive (group A) and resistant (group B). Data are presented as a scatterplot of normalized p value/false discovery q value vs normalized enrichment score (NES) for each evaluated gene set. The red dots highlight cell cycle and Rb-E2F pathway gene sets.

**(D)** GSEA show that genes highly expressed in GSK-J4 sensitive (group A) cells are enriched with Rb1 knockout.

**(E)** Quantitative comparison of all chemical and genetic perturbation gene sets ( $n = 3403$ ) from the MSigDB by gene set enrichment analysis (GSEA) for GSK-J4 sensitive and resistant neuroblastoma cells, as shown in the right panel of cell lines. Data are presented as a scatterplot of normalized p value/false discovery q value vs normalized enrichment score (NES) for each evaluated gene set. The red and green dots highlight cell cycle and Rb-E2F pathway gene sets and MYC gene sets, respectively.

**(F)** Crystal violet staining of colonies after SK-N-SH and SK-N-FI neuroblastoma cell lines were treated with different concentrations of GSK-J4 for 7 days.





# **Figure 4. KDM6B inhibition represses chromatin accessibility of E2F genes.**


**(A)** ATAC-seq was performed after BE2C cells were treated with 2.5μM of GSK-J4 for 48 hours. Summary of peak calling number of ATAC-seq ( $p < 0.05$ ,  $\log_2$  fold change  $\geq 0.5$ ) including the upregulated and downregulated nucleosome free regions, and the annotated locations of the peaks at defined promoter and enhancer regions.

**(B)** Snapshot of *AKT1* locus using Integrative Genomic Viewer (IGV) for ATAC-seq, H3K27Ac ChIP-seq, and RNA-seq. The ATAC-seq analysis shows the downregulation of two peaks at the 5' promoter region of *AKT1* and one peak at the non-coding RNA *LINC00638*. The RNA-seq results showed that the *AKT1* transcript was downregulated by 48h of GSK-J4 treatment and KDM6B knockdown. H3K27Ac in BE2C cells was referenced to GSM2113518<sup>109</sup>.

**(C)** Snapshot of *E2F8* locus using Integrative Genomic Viewer (IGV) for ATAC-seq, H3K27Ac ChIP-seq, and RNA-seq. The ATAC-seq shows the downregulation of three peaks at the enhancer region of *E2F8*, next to the *NAV2* gene locus. The RNA-seq results showed that *E2F8* transcript was downregulated by KDM6B inhibition while the adjacent *NAV2* expression is barely detectable.

**(D)** Cartoon indicates the rationale of footprinting analysis. The DNA motifs bound by transcription factors such as E2F1 protect the cut from transposase Tn5, while the adjacent open chromatin gives rise to a high signal of nucleosome free region after ATAC-seq analysis. After GSK-J4 treatment, the open chromatin was repressed and consequently reducing the reads of free DNA.

**(E)** Footprinting plot shows the reduction of open chromatin at predicted binding motifs of E2Fs and MYC after BE2C cells were treated with GSK-J4 for 24 h and 48h.




# **Figure 5. KDM6B inhibition induces an increase of H3K27me3 but a decrease of the enhancer mark H3K4me1 at CTCF and BORIS binding sites**

**(A, B)** Heatmap indicating the CUT&Tag signal intensity of H3K27me3 (A) and H3K4me1(B) around differentially expressed genes (from TSS-5kb to TES+5kb). CUT&Tag experiments were done with two biological replicates in KDM6B knockdown and GSK-J4 treatment respectively. Differentially expressed genes were identified by cutoffs ( $\log_2FC > 0.5$ ) from RNA-seq. TSS= transcription start site, TES=transcription end site

**(C)** The signals of H3K27me3 and H3K4me1 (CUT&Tag), H3K27Ac (ChIP-seq)<sup>109</sup>, and ATAC-seq between the genomic locus of *MYCN*, *GACAT3*, and *FAM149A*, snapshot using IGV program.

**(D, E)** Motif analysis of H3K27me3 (D) and H3K4me1 (E) peaks by using HOMER known motif search. Top ten most significant motifs from each sub-group were visualized as a heatmap. The heatmap scale indicates  $-\log_{10}(p \text{ value})$ .

**(F)** The Hi-C data of BE2C neuroblastoma cells (data extracted from the St Jude Cloud) showing that *MYCN* and its adjacent *FAM149A* locus reside in the same topologically associated domain (TAD). The Arc indicates the chromatin interactions, which were generated from Jurkat ChIA-PET SMC1 (Mango) (<https://proteinpaint.stjude.org/>).



# **Figure 6. GSK-J4 induces a transcriptome that mimics CDK4/6 inhibition, and vice versa**

**(A)** Genes downregulated by KDM6B knockdown were compared with gene profiles induced with chemical compounds from Library of Integrated Network-Based Cellular Signatures (LINCS). The top chemical signature hits, which are basically overrepresented by palbociclib, are highlighted in pink dots.

**(B)** Same analysis performed as in (A) for GSK-J4 treatment.

**(C)** The 89-gene signature derived from palbociclib treatment of 4 neuroblastoma cell lines was included in gene sets for GSEA analysis of KDM6B knockdown.

**(D)** The 89-gene signature derived from palbociclib treatment was included in gene sets for GSEA analysis of GSK-J4.

**(E)** BE2C cells were seeded with low numbers in 6-well plate and treated with different concentrations of GSK-J4 or/and palbociclib for 10 days. The cell colonies were stained with crystal violet.

**(F)** Bliss index for the combination of GSK-J4 and palbociclib. Positive scores indicate synergy, negative scores indicate antagonism.

**(G)** Western blot to assess the expression of CDK4 and CDK6 that were transduced into BE2C cells.

**(H)** The BE2C parental and CDK4/6 overexpressing cells were seeded with low numbers in 6-well plate and treated with different concentrations of GSK-J4 or palbociclib for 8 days. The cell colonies were stained with crystal violet.


**(I, J)** BE2C and CDK4 or CDK6 overexpressing BE2C cells (BE2C-CDK4-OE, BE2C-CDK6-OE) were treated with different concentrations of palbociclib (I) or GSK-J4 (J). EC50 was calculated using Prestoblu assay.

**(K)** Western blot to assess the expression of pRB after inducible knockout in BE2C cells.

**(L)** Photos taken under microscope (10x) show Rb1 knockout leads to resistance to palbociclib.

**(M)** The BE2C wildtype and Rb1 knockout cells were seeded with low numbers in 6-well plate and treated with different concentrations of GSK-J4 or/and palbociclib for 8 days. The cell colonies were stained with crystal violet.






**Figure 7. A gene signature targeted by KDM6B inhibition is associated with poor outcome**

(A) 149-gene signature was uploaded into R2 genomics analysis program (<https://hgserver1.amc.nl/cgi-bin/r2/main.cgi>) to find the differentially expressed genes in high-risk neuroblastoma in a cohort dataset (GSE49710) that has 498 neuroblastoma cases, followed by k-means cluster analysis. Risk (Red =high risk; green =low risk); MYCN (red = Amplification; green = non-Amplification); Stage (red = stage 4; blue= stage 4S; brown =stage 3; dark green = stage 2, green= stage 1).

(B-C) Kaplan-Meier curve using Log-Rank method shows the event-free survival and overall survival of 4 clusters that have differential expression levels of GSK-J4 signature.

(D, F) Kaplan-Meier curve using Log-Rank method shows the event-free survival and overall survival of clusters 3 and 4 with MNA.

(E, G) Kaplan-Meier curve using Log-Rank method shows the event-free survival and overall survival of clusters 3 and 4 with high-risk disease.



**Figure 8. Working model of KDM6B inhibition in neuroblastoma.**

(A) Upon stimulation by mitogens, KDM6B is recruited to chromatin to maintain the low levels of H3K27me3 at the distal regulatory enhancer regions marked by H3K4me1 overlapping with the CTCF/BORIS binding sites, which loops and physically interacts with E2F that binds at the promoter of target genes, together with associated transcriptional machinery including RNA polymerase II and mediators, driving the MYCN and E2F transcriptome.

(B) When inhibited by CDK4/6 inhibitor, the inhibitory pRB complexes with HDAC to suppress gene transcription. When KDM6B is inhibited by GSK-J4, the H3K27me3 will accumulate at the distal regions to displace the H3K4me1 modifier KMT2 and evicts the transcription activators of promoter-enhancer, leading to the downregulation of MYCN and E2F transcriptome (Figure 7B).

(C) A network composed by MYCN, E2F, EZH2 and KDM6B regulates the cell proliferation and differentiation of neuroblastoma.

**Table 1. Transcription factor binding motif enrichment for KDM6B target genes (top15)**

	<b>Gene Sets</b>	<b>NES</b>	<b>NOM p-val</b>	<b>FDR q-val</b>
1	KRCTCNNNNMANAGC_UNKNOWN	2.76	0	0
2	SGCGSSAAA_E2F1DP2_01	2.17	0	0
3	TTTNNANAGCYR_UNKNOWN	2.14	0	0
4	E2F4DP1_01	2.1	0	0
5	E2F_03	2.06	0	0
6	E2F1_Q6	2.03	0	0
7	E2F_02	2.03	0	0
8	E2F_Q6	2.02	0	0
9	E2F_Q3	2.01	0	0
10	E2F4DP2_01	2	0	0
11	E2F1DP2_01	2	0	0
12	E2F1DP1_01	1.99	0	0
13	E2F_Q4	1.99	0	0
14	E2F_Q6_01	1.92	0	0
15	E2F1_Q6_01	1.9	0	0

**Table 2. Transcription factor binding motif enrichment for GSK-J4 target genes (top 15)**

	<b>Gene sets</b>	<b>NES</b>	<b>NOM p-val</b>	<b>FDR q-val</b>
1	KRCTCNNNNMANAGC_UNKNOWN	2.43	0	0
2	SGCGSSAAA_E2F1DP2_01	1.48	0.003	0.253
3	E2F_01	1.42	0.037	0.31
4	E2F_Q3	1.39	0.012	0.325
5	TTTNNANAGCYR_UNKNOWN	1.39	0.023	0.262
6	E2F_Q6	1.36	0.012	0.274
7	E2F1_Q3	1.33	0.015	0.308
8	E2F4DP1_01	1.32	0.018	0.301
9	E2F1_Q6	1.32	0.02	0.269
10	E2F_Q4	1.31	0.013	0.273
11	RGTTAMWNATT_HNF1_01	1.31	0.071	0.25
12	E2F1DP2_01	1.29	0.027	0.268
13	E2F_02	1.28	0.028	0.266
14	E2F1_Q6_01	1.28	0.042	0.255
15	E2F1DP1_01	1.28	0.037	0.246

**Table 3. Transcription factor binding motif enrichment for neuroblastoma cells sensitive to GSK-J4**

	<b>Gene Sets</b>	<b>NES</b>	<b>NOM p-val</b>	<b>FDR q-val</b>
1	E2F_Q6	1.89019	0.00000	0.00000
2	E2F_Q4	1.86916	0.00000	0.00112
3	E2F4DP2_01	1.84061	0.00000	0.00075
4	E2F_Q2	1.83652	0.00000	0.00112
5	E2F1DP1_01	1.83527	0.00000	0.00090
6	E2F1_Q6	1.83142	0.00000	0.00075
7	E2F1DP2_01	1.83124	0.00000	0.00064
8	E2F1_Q3	1.82484	0.00000	0.00056
9	E2F1DP1RB_01	1.80926	0.00000	0.00050
10	E2F4DP1_01	1.80680	0.00000	0.00045
11	E2F_Q3_01	1.80364	0.00000	0.00041
12	E2F_Q3	1.79745	0.00000	0.00064
13	SGCGSSAAA_E2F1DP2_01	1.79145	0.00000	0.00076
14	E2F1_Q4_01	1.77454	0.00000	0.00125
15	E2F_Q4_01	1.77275	0.00000	0.00117
16	E2F_Q6_01	1.71608	0.00000	0.00258
17	E2F1_Q6_01	1.67011	0.00000	0.00468
18	E2F_Q3	1.66943	0.00000	0.00448
19	KRCTCNNNNMANAGC_UNKNOWN	1.63733	0.00184	0.00603
20	NRF1_Q6	1.55445	0.00000	0.01859
21	NRSF_01	1.54447	0.00000	0.01968
22	TMTCGCGANR_UNKNOWN	1.52952	0.00000	0.02146
23	CAGNWMCNNGAC_UNKNOWN	1.52403	0.00000	0.02186
24	ACTAYRNNNCCCR_UNKNOWN	1.51553	0.00000	0.02396
25	MCAATNNNNNGCG_UNKNOWN	1.51439	0.00372	0.02336